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Alzheimer’s disease (AD), a common debilitating neurodegenerative disease, is a major 
public health problem in the United States because it affects almost 50% of the people after age 
85.  Although AD has been described since 1907, no cure or universally accepted effective 
treatment has been devised.  Studying factors that play a role in risk and pathogenesis of LOAD 
may lead to development of new therapies and give an insight to the etiology of disease.  Both 
genetic and environmental factors have been implicated in the etiology of AD.  Twin studies 
have shown heredity to be a major causal factor in the development of LOAD.  Despite the 
evidence for substantial genetic effect in the etiology of LOAD, the APOE*4 allele in the APOE 
gene is the only established risk factor in the development of LOAD.  However, as the APOE*4 
allele is neither necessary nor sufficient for the development of AD, this emphasizes the 
involvement of other genetic and/or environmental factors, which alone or in combination with 
APOE*4 can modify the risk of AD.  Recently, linkage studies in multiplex families with LOAD 
have provided evidence for the existence of additional putative genes for AD on several 
chromosomes, including chromosome 10. A broad linkage peak encompassing >50 cM region 
between chromosome 10q21 and 10q25 has been implicated that influence both AD risk and age-
at-onset (AAO).  There are more than 300 genes in this broad genomic region of chromosome 10 
and thus task for identifying the chromosome 10 gene is daunting.  One approach is to focus on 
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the known candidate genes in the region.  There are number of promising candidate genes 
in this region that are involved in either in the production, processing or clearance of Aβ 
peptide and include choline acetyltransferase (CHAT), plasminogen activator, urinary 
(PLAU), insulin-degrading enzyme (IDE), hematopoietically expressed homeobox 
(HHEX), glutathione S-transferase, omega-1 (GSTO1), glutathione S-transferase, omega-
2 (GSTO2), and protease, serine, 11 (PRSS11). In this study, we have examined the role 
of these genes under the linkage peak on chromosome 10 to assess their role with AD risk 
and AAO.  Association studies for 14 markers were performed in a large case-control 
cohort comprising 1012 white LOAD subjects and 771 white control subjects.  No 
significant associations were observed with any of the polymorphism examined in the 
IDE, HHEX, GSTO1, GSTO2 and PRSS11 genes.  Of the 3 CHAT SNPs examined, we 
detected both allelic and genotypic association of the intron 9 polymorphism with AD 
risk.  The rare AA genotype appears to confer a modest risk for the development of AD 
in a recessive fashion (OR: 2.37; p=0.007). In addition, we observed APOE-dependent 
effect of the CHAT exon 5 polymorphism with AD risk (OR=0.76; p=0.046).  Although 
these associations are modest, they suggest the presence of putative functional variants in 
the CHAT gene or nearby genes.  In the PLAU gene, we examined 3 tagSNPs and found 
a modest protective effect with one SNP in the 3’ UTR (OR=0.71; p=0.02), which was 
confined to APOE*4 carriers (OR=0.58; p=0.02).  In our analysis of the association of 
the candidate genes with AAO, suggestive association were observed only with the 
PLAU 3’ UTR (p=0.10) and intron 9 (p=0.04) polymorphisms. 
In summary, our data on a large number of AD cases and controls suggest that 
genetic variation in two positional candidate genes on chromosome 10 (PLAU and 
CHAT) may affect the risk and AAO of LOAD. 
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1. Background and Significance 
 
 
 
Alzheimer’s disease (AD), the most common form of dementia among the elderly, is a 
progressive, degenerative disorder of the brain with a loss of memory and cognition.  A defining 
characteristic of AD is the deposition of amyloid fibrils and neurofibrillary tangles in the brain of 
afflicted individuals; biochemically, they are mainly composed of β-amyloid protein (Aβ) and 
phosphorylated tau proteins, respectively (Burns et al.1970; Selkoe, 2000).  The precise 
biochemical pathways leading to AD are presently unknown.  Alzheimer’s disease is an age-
dependent disorder.  The prevalence of AD increases exponentially with age estimates showing 
that it increases from 10% at age 65 years to nearly 50% after age 85 years.  A person with AD 
lives an average of 8 years, but some patients live 20 years or more following the onset of 
symptoms.  
 
 
1.1.  Signs, Symptoms and Cause 
 
Alzheimer’s disease is a progressive, neurodegenerative disease of the brain.  Alzheimer disease 
is characterized by more than just memory loss; it also results in other cognitive and behavioral 
symptoms that progressively impair function in activities of daily living. The cognitive 
symptoms include memory loss, disorientation, confusion, problems with reasoning and 
thinking. Behavioral symptoms include agitation, anxiety, delusions, depression, hallucinations, 
insomnia, and wandering. 
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 Alzheimer disease is a genetically complex and heterogeneous disorder, as both genetic 
and environmental factors play a role in development of AD. Mutations in three genes are 
involved in early onset AD: β-amyloid protein precursor (APP) gene on chromosome 21 (Goate 
et al.1991), the presenilin 1 (PS1) gene on chromosome 14 (Sherrington et al 1995), and 
presenilin 2 (PS2) gene on chromosome 1 (Levy-Lahad et al. 1995; Rogaeva et al. 1995). 
However, these mutations account for only a small percentage of all AD patients young and old.  
Genetic variation in the APOE gene has been identified to be a strong risk factorfor LOAD that 
explains nearly 20-30 % of risk (Slooter et al. 1998, Seshadri et al.1995).  However, as APOE 
genetic variation is neither necessary nor required for AD, additional genetic and /or 
environmental factors are thought to be involved in the etiology of LOAD.  Many risk factors are 
under investigation for association with AD. For example, certain genes make some families 
vulnerable, head injuries may increase risk, and high blood pressure is a new suspect (Kalaria, 
2001; Mark, 2001). The established risk for AD is age: cases double with every 5 years as 
patients age between 65 and 85.  
 
 
1.2.  Environmental factors 
 
No specific environmental toxin has been found to be associated with AD. While depression, 
smoking, traumatic head injury and cardiovascular-related disorders such as hypertension, 
myocardial infarct, hypercholesterolemia and stroke have been associated with AD, it remains 
unclear whether these are true antecedents or simply comorbidities (Mayeux et al. 2003). 
Variation in socioeconomic factors such as literacy, educational achievement and the type of 
early home environment have been associated with AD (Stern et al. 1994; Friedland et al. 2001), 
but the mechanism by which these factors are related to disease remain uncertain. The use of 
2 
 estrogen, anti-inflammatory drugs, the consumption of wine and devoting time to complex 
physical and mental activities have been related to decreased risk (Tang et al. 1996; Yaffe et al. 
2000, Orgogozo et al.1997; Laurin et al. 2001; In't Veld et al. 2001).  
 
 
1.3. Apolipoprotein E 
 
Apolipopretein E (APOE), a 34 kDa molecular weight protein, is product of a single gene on 
chromosome 19.  APOE is a plasma lipoprotein that is one of the principal constituents of 
chylomicrons and very low density lipoproteins (VLDL), playing a vital role in cholesterol 
transport. Its primary site of biosynthesis is the liver, but the second major site of synthesis is the 
brain.  In the central nervous system, APOE is produced by astrocytes and microglia and has an 
essential role in transporting lipids from astrocytes to injured neurons for repair (Poirier et al. 
1994).  APOE is a protein with roles in lipid metabolism and tissue repair.  Like APP, the 
synthesis of APOE is up-regulated after the nervous system has been damaged (Horsburgh et al. 
1996). 
The APOE gene is polymorphic with the existing of three alleles that code for E2, E3, E4 
isoforms that differ from each other by one amino acid only: while E3 has cysteine at position 
112 and arginine at position 158, E2 has Cys at both position and E4 has Arg at both positions.   
APOE is associated with both risk and AAO of AD (Meyer et al. 1998).  Family studies led to the 
identification of APOE as a susceptibility  gene because possession of a single APOE*4 allele, 
present in approximately 25% of the Caucasian population, is associated with a two- to three-
fold increase in disease risk, while having two copies is associated with a five-fold rise.  Unlike 
the early onset mutations, the APOE*4 allele is not fully penetrant, and the population 
attributable risk has been estimated at 20%-30% (Slooter et al.1998; Seshadri et al. 1995).  More 
3 
 significantly, there is dose-dependent relationship between the number of APOE*4 alleles and 
the AAO of AD such that E4/E4 subjects have an earlier onset than heterozygous E4 subjects 
(Corder et al. 1993, Meyer et al.1998).  Subjects with an APOE*2 allele, on the other hand, have 
a later onset (Corder et al. 1994) However, this association is weaker with advanced age at onset, 
and the putative protective role of the APOE*2 allele is not clear.  
In addition to the APOE E2/E3/E4 coding sequence polymorphism, several 
polymorphisms have been discovered in the 5'-promoter of the APOE gene,  (Lambert et al. 
1998; Town et al.1998) as well as a missense mutation at codon 28 (Kamboh et al. 1999).  The 
promoter polymorphisms are believed to affect the risk of AD independently of APOE*4, due to 
altering the transcriptional activity of APOE.  However, several other studies have been unable 
to replicate these findings (Song et al. 1998; Schellenberg et al. 1992).  One of the reasons for 
this inconsistency seems to be due to use of relatively small sample sizes in published studies.  
This becomes an important issue for those markers that have small effects on the disease risk.  It 
appears that the effect of the APOE promoter polymorphism is small relative to established 
impact of APOE the E2/E3/E4 polymorphism. 
 
 
 
2. Alzheimer’s Disease Gene in Chromosome 10 
 
 
 
Genome-wide linkage studies on AD show that this is a genetically complex disorder involving 
several genes in addition to APOE.  Linkage studies have identified several promising 
chromosomal regions that may harbor additional AD genes, including chromosome 10 (figure 
2.1). 
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 Initially, linkage to chromosome 10 was reported by Kehoe et al. (1999) in a genome-
wide screen of LOAD sibling pairs.  On follow-up, linkage to the same region on chromosome 
10 with a maximal lod score of 3.83 at 81 cM close to D10S1225 was confirmed (Myers et al. 
2000).  Linkage to the same region was replicated in a genome-wide screen of LOAD sibling 
pairs by the same group (Myers et al 2002).  They performed a two-stage screen, first genotyping 
markers at 20 cM intervals in 292 affected sibling pairs using 237 markers, then examining 
regions with a LOD score  1 in an additional 91 markers in the 16 regions.  
There is evidence that a quantitative trait locus for high amyloid β42 (Aβ42) levels maps 
to the same chromosomal region (Ertekin-Taner et al. 2000).  It has been shown that the 
processing of APP is a critical step in the pathogenesis of AD.  Most mutations in the known 
genes involved in autosomal dominant inherited forms of AD (APP, PS1, and PS2) cause an 
increase in Aβ42 levels in patients (Scheuner et al. 1996) by affecting the processing of APP.  
Ertekin-Taner et al. (2000) collected families with increased plasma Aβ42 levels and screened 
them for quantitative trait loci (QTL) controlling Aβ levels.  They hypothesized that risk loci for 
high plasma Aβ would also be risk loci for AD and thus focused on the regions Kehoe et al. 
(1999) had found in their first study.  Indeed, linkage to Aβ42 levels was observed near 
D10S1225 on chromosome 10 with a maximal lod score of 3.93 at 81 cM.  These results provide 
strong evidence for a novel LOAD locus on chromosome 10 that acts to increase Aβ. 
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Figure 2.1 Map position of reported linkage results for the risk and AAO genes for AD on chromosome 10q 
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On the other hand, Bertram et al. (2003) identified a putative susceptibility locus about 30 cM 
distal to D10S1225 at 94 cM near D10S583.  Bertram et al. (2000) genotyped six markers 
surrounding the insulin degrading enzyme (IDE) gene, since IDE is thought to be a good 
candidate gene for LOAD due to its putative role in the degradation of Aβ (Vekrellis et al. 2000).  
They also genotyped marker D10S1225, a marker within same linkage peak implicated by others 
(Kehoe et al. 1999; Myers et al. 2000; Ertekin-Taner et al. 2000).  They found a maximum Z-
score for the likelihood ratio of 2.1 at D10S1710 in the subset of their sample, which had AAO 
 65. This marker is located 9 cM away from IDE and 42 cM away reported by Myers et al 
(2000). 
Using different set of markers in the same sample, the same group observed MLS of 0.9 
at 115.8 cM, which lies about 9 cM distal to their early reported peak (Blacker et al. 2003).  In 
order to gain a better understanding of the broad signal on chromosome 10, additional analyses 
of the chromosome 10 data were performed in GENEFINDER, which estimates the location and 
a 95% confidence interval for an unobserved trait locus using multipoint marker information to 
approximate identity by descent (IBD) sharing in affected sib pairs, yielded strong signals with 
overlapping confidence intervals across a very broad region from 62 to 131 cM in the late-onset 
stratum (with Z-scores ranging from 2.5 (p=0.006) to 3.1 (p=0.001)), while the early/mixed 
stratum had a weaker but somewhat narrower signal from 13 to 37 cM (Z-score 1.6 (p=0.054)). 
Thus, it is still unclear whether there are one or two underlying genes located on the long arm of 
chromosome 10. 
Recently, Li and colleagues (2002) have analyzed their data using AAO as a quantitative 
trait, and reported a peak around 125 cM, which is closer to the linkage region identified by 
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 Bertram et al. (2000) (between 115 and 127 cM), but different from other locations (Bertram et 
al. 2000; Ertekin-Taner et al. 2000; Myers et al. 2000).  Li et al.(2002) propose three possible 
explanations for the previously reported inconsistent localizations of risk genes on chromosome 
10;  i) the same gene may affect both risk of AD and onset in a subset of families, ii) different 
genes located within this region may affect risk and onset, or iii) It is the effect of AAO rather 
than risk detected by statistical methods. 
 
 
2.1. Candidate Genes on Chromosome 10 
 
There are several candidate genes under the linkage peaks on chromosome 10.  Glutathione S-
transferases (GSTs) are a superfamily of enzymes with broad range of substrates and catalytic 
activities.  Utilization of glutathione in reactions contributes to the transformation of a wide 
range of exogenous and endogenous compounds, including carcinogens, therapeutic drugs, and 
products of oxidative stress. (OMIM 60548)  GSTO1 and GSTO2 are located next to each other 
on chromosome 10q24.3 and composed of six exons (Fig.2.2). 
 
 
 
Figure 2.2 The locations of candidate genes used by Li et al. (2003) to examine their association with AD.  The 
solid black boxes indicate the genes significantly down regulated in the microarray study. The short vertical lines 
represent the SNPs genotyped in the AD dataset.  
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GSTO2 has 64% amino acid identity with GSTO1.  GSTO1 is expressed in a wide range 
of tissues, specifically
 
 polymorphism as well as GSTO2/C → T polymorphism 
with A
e is encoded by 10 
exons 
 neural glial cells (Board et al. 2000).  Li et al. (2003) have reported the 
association of GSTO1/ Ala 104 Asp
AO for both AD and PD, but not the risk of disease.  Although the functions of GSTO1 
and GSTO2 are not well understood, study by Laliberte et al. (2003) suggests that they may be 
involved in the activation of IL-1ß.   
Serine protease 11 (PRSS11), is a 480-amino acid protein. The gen
and 9 intervening introns.  It is located on chromosome 10q25.3-q26.2 (Zumbrunn and 
Trueb, 1997), which is about 18 Kb downstream of the GSTO1/GSTO2 (fig2.2).  Li et al. (2003) 
demonstrated a significant association of a PRSS11/T→C with AAO of AD. 
Insulin-degrading enzyme (IDE) plays a role in degradation of number of peptides, 
including insulin and beta-amyloid.  Since deposition of Aβ is one of the hallmarks in the 
pathology of AD, the role of IDE in the clearance of Aβ makes it a good candidate gene for AD.  
Animal studies supported the viability of this putative mode of action, in that IDE deficiency has 
been shown to promote significant net increases in Aβ deposition in mouse brain (Farris et al. 
2003; Miller et al.2003).  IDE is located on chromosome 10q23–q24, a region in which a 
susceptibility locus for AD has been mapped.  Two linkage studies reported distinct linkage 
peaks close to the IDE region (Bertram et al. 2000; Li et al. 2002).   Despite the linkage data, 
several case control studies (Abraham et al. 2001; Boussaha et al. 2002; Edland et al. 2003; 
Sakai et al. 2004) did not provide any convincing evidence of association for IDE and AD.  
However, in a comprehensive study by Prince et al. (2003), significant associations with the 
severity of disease, as measured by quantitative traits such as Mini-Mental Examination Scores 
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 (MMSE), protein tau levels in cerebral spinal fluid, the AAO, and degree of brain pathology was 
found.  Prince et al. (2003) concluded that the effect of IDE might be in the severity of the 
disease rather than on disease risk.  A recent study by Ertekin-Taner et al. (2004) replicated the 
results of Prince et al. (2003) in case-control series and also found significant association of IDE 
haplotypes with plasma Aβ42.  The only possible association with AD risk reported by Edland et 
al. (2003) among non-APOE*4 carriers had too small a sample size for meaningful 
interpretation.  Although IDE is an excellent candidate functionally and positionally as a gene 
involved in AD, association of IDE with AD risk is yet to be established. 
 
Figure 2.3  Genomic structure of the CHAT gene (Harold et al. 2003) 
 
The gene for choline acetyltransferase (CHAT), an enzyme responsible for acetylcholine 
biosyntheses in cholinergic neurons, is located under the linkage peak on chromosome 10 
(Bertram et al. 2000).  In humans, CHAT may be produced in 82- and 69-kDa forms and encodes 
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 5 splice variants: M, N1, N2, R, and S.  While human M and S type mRNAs have the capability 
of generating both large and small form of CHAT proteins,  R and N-type CHAT mRNAs 
generat
ese data support the role of CHAT in the 
dev
e only small form of CHAT protein.  The first intron of CHAT harbors SLC18A3 or 
vesicular acetylcholine transporter (VACHT) proteins (Fig 2.3).  A single regulatory locus 
controls the transcription of both genes and they are referred to as the cholinergic gene locus. 
CHAT is essential for cholinergic neurotransmission (Nachmansohn et al. 1943).  One of 
the characteristic features of AD is the selective degeneration of cholinergic neurons among 
different populations of nerve cells.  Reduced CHAT activity has been shown to cause damage to 
cholinergic neurons in neurodegenerative diseases such as AD (Perry et al.1978; Whitehouse et 
al 1982; Oda 1999).  Additionally, the concentration of CHAT is markedly reduced in AD brains 
compared to controls.  (Oda  1999; Bartus et al. 1982).  It has been shown that degree of 
reduction in the cerebral CHAT activity and acetylcholine (ACh) synthesis is strongly correlated 
with the severity of dementia (Wilcock et al. 1982), suggesting that cellular loss and dysfunction 
of cholinergic neurons result in the development of dementia in AD.  Furhermore, Lin et al 
(1999) have demonstrated that cognitive deficits induced by cholinergic lesions correlate with 
APP protein levels in the cerebral cortex and  that cholinergic muscarinic receptors participate in 
the regulation of APP metabolism. Additionally, Aβ has been shown to decrease both choline 
uptake and ACh release in rat biopsy (Kar et al. 1998). These findings suggest that cholinergic 
neurotransmission may be a specific target for Aβ.  Th
elopment of AD.   An original study reported by Mubumbila et al. (2002) found a significant 
association of a CHAT missense mutation with AD, but subsequent studies failed to confirm this 
association (Schwartz et al. 2003; Harold et al. 2003). 
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 Plasminogen Activator, Urinary (PLAU) converts plasminogen to plasmin.  Plasmin is 
involved in the processing of amyloid precursor protein, one of the hallmarks of AD (Finckh et 
al. 2003).  PLAU is located on chromosome 10q22.2 between two regions showing linkage to 
LO
y that makes it difficult to replicate genetic association studies, 
and thus additional functional and genetic association studies are needed to confirm or to refute 
the original associations.  In this study, we propose to assess the reported associations in 
biological and positional candidate gene in a large and independent case control cohort from the 
University of Pittsburgh ADRC. 
AD.  Studies by Finckh et al. (2003) demonstrated that a Pro141Leu polymorphism in the 
PLAU gene was associated with the risk of AD.  However, another group examined this 
polymorphism along with 7 others spanning the entire gene and found no association with any of 
the polymorphism examined (Myers et al. 2004). 
The complex set of genetic and environmental factors that contribute to common diseases 
like LOAD produce heterogeneit
12 
  
 
3. Specific Aims 
 
 
 
The objective of this study was to examine the association of multiple polymorphisms in 7 
positional and biological candidate genes on chromosome 10 with the risk and AAO of AD. 
 
Hypothesis1:  Chromosome 10 genes affect the risk of AD independent of the APOE 
E2/E3/E4 polymorphism. 
Hypothesis2: Chromosome 10 genes affect AAO of AD independent of the APOE 
E2/E3/E4 polymorphism. 
Hypothesis3: Chromosome 10 harbors independent liability genes for AD risk and AAO 
and their effects are independent of the APOE E2/E3/E4 polymorphism. 
Hypothesis4: The effects of the chromosome 10 genes on AD risk and AAO are 
dependent on the APOE E2/E3/E4 polymorphism. 
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4.  Research Design and Methods 
 
 
 
This project is a case-control study designed to test the association of genetic variations within 
candidate genes with the risk and AAO of AD.  The subjects in this study are all Caucasian 
Americans (Table 4.1).  All patients are sporadic, late onset (≥60 years) AD cases from the 
University of Pittsburgh Alzheimer Disease Research Center (ADRC).  The controls are 
recruited from three different sources: 1) University of Pittsburgh ADRC, 2) Monongahela 
Valley Independent Elders Survey (MoVIES) and 3) White Matter Hyperintensity Study.   
 
4.1.  Subjects 
 
4.1.1. Patients 
 
A total of 1012 white patients (63.21% female) from the University of Pittsburgh ADRC was 
used for this study (Table 4.1).  The mean age is 76.57 ± 5.7 years with a mean age at onset of 
72.29 ± 6.33 years.  Among the patients, 280 (25.2%) are autopsy confirmed AD cases.  Clinical 
diagnoses of the patients were made according to the NINCDS/ADRDA criteria (McKhann et al. 
1984).  The ADRC follows a standard evaluation protocol, which includes medical history, 
general medical and neurological examinations, a psychiatric interview, neuropsychological 
testing and a MRI scan. 
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 4.1.2. Controls 
 
A total of 771 controls was used from three resources at the University of Pittsburgh. 
There are 159 (57.2% female) white controls from the ADRC cohort with a mean age of 73.36 ± 
3.71 years. Control subjects are considered normal after undergoing clinical and 
neuropathological examinations as followed by the ADRC evaluation protocol. 
Four hundred twenty six subjects (66.4% female) with a mean age of 77.46 ± 4.18 years that 
have a MMSE score above 25 on test number 5 were obtained from the Monongahela Valley 
Independent Elders Survey (MoVIES) cohort.  MoVIES is a prospective community study of 
cognitive impairment and dementia in the rural mid-Monongahela Valley region of southwestern 
Pennsylvania (Ganguli et al. 1991).  Subjects have not undergone the standard ADRC clinical 
evaluation, but have had clinical and neuropsychological assessment and are known to be high 
functioning and non-demented.  There are 120 (50% female) subjects available from the White 
Matter Hyperintensity Study (WHM) study with a mean age of 73.7 ± 3.3 years.  Although the 
subjects did not undergo ADRC clinical diagnostic protocol, they have been assessed as non-
demented using standard cognitive tests.  WMH is a study of normal aging served by University 
of Pittsburgh Western Psychiatric Institute and Clinic. 
To examine the comparability between the cases and controls we performed the 
comparison between the two groups in terms of age, sex, education, MMSE score, and family 
history (Table 4.1).  The cases and controls found to be similar for age education and family 
history of dementia.  As expected, the cases and controls are significantly different from each 
other in their MMSE scores (Table 4.1). 
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 Table 4.1 Composition of the Case-Control Cohort 
                
       
      Control (771) Cases (1012) p value 
        
Age±SD(year)  76.10±4.98 77.26±6.08 0.22 
Female   63.21%  66.9 % 0.35 
Education±SD(year)  13.07±3.04 12.04±3.10 0.15 
Familly History of Dementia 38.29%  40.96%  0.51 
MMSE score±SD  28.04±1.51 17.01±6.20  
                
        
 
 
4.2. DNA Isolation and PCR 
 
Genomic DNA has been isolated from buffy coat or brain biopsy tissue using the QIAamp kit 
(QIAGEN).  Briefly, 1 µg of genomic DNA is amplified in a 50 µl reaction mixture consisting of 
5 µl of 10 X PCR buffer (100 mM Tris-HCl, pH= 8.3, 500 mM KCl), 1.0-2.5 mM MgCl2, 
1.25mM of each dNTP (Pharmacia), 0.2 µM of each primer, and 1.25 units of Taq DNA 
polymerase (Display Biosystems) or 9:1 mixture of Amplitaq Gold (Perkin Elmer) and Pfu 
polymerase (Strategene).  Genotyping was performed using standard polymerase chain reaction 
(PCR) procedures.  After initial denaturation of 95 °C, the reaction mixture is subjected to 45 
cycles of denaturation of 30 sec at 95 °C, annealing for 30 sec at a particular temperature, and a 
extension for 30 sec at 72 °C.  This was followed by a final extension step for 10 minutes at 72 
°C (table 4.2).  The correct size and purity of amplified product is verified by running 5 µl of 
PCR product on a 2 % agarose gel. 
The polymorphisms were screened by using restriction enzyme analysis or 
pyrosequencing methods.  Restriction endonucleases were chosen (Mac DNAsis Program) 
16 
 whenever the genetic variant creates or abolishes a restriction site.  Pyrosequencing is method for 
performing genotyping through sequencing by synthesis and capable of analysis of genetic 
diversities such as bi-, tri- and tetra-allelic polymorphisms, multiple SNPs, mutation, and 
insertion/deletions.  PCR products are converted to single stranded templates onto which a 
sequencing primer is annealed in 96 well plates.  Analysis begins with dispensation of the 
substrate-enzyme reagents into the wells containing test samples. Light is produced when a 
nucleotide forms a base pair with its compliment. The light and base are registered by a charge 
coupled device (CCD) camera, and is seen as a peak.  If the next nucleotide added to the 
template is not complimentary to the nucleotide base, no light is detected on the CCD. The 
height of the peaks is proportional to the number of bases that have been integrated.  Software 
used with the PSQ-96MA automatically analyzes the quantitative data. The data can be evaluated 
by the user on computer as well.  The software allows for multiplex genotyping of up to three 
polymorphisms in a single well. 
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 Table 4.2 PCR condition for markers on chromosome 10 
SNP ID 
 
 
SNP 
Fragment
(bp) 
 
Conditions
 
Primer sequence 5'->3' 
 
Additional 
information 
CHAT-rs868750 G>A 156 56 °C R:GTGGCCATGCGTTCACGT biotin 
CHAT-rs868750       F:CGGCTCTCATTCTTAGAAGGCAAC   
CHAT-rs868750       seqR:ACTGGAAGTAGGGGC   
CHAT-rs3810950 A>G 64 56 °C F:ACTCACCAAGACGCCCATC   
CHAT-rs3810950       R:ACTGCTGGGAGTTTTTGCT biotin 
CHAT-rs3810950       seqF:GGTCCCCCGTAAGAT   
CHAT-rs1880676 A>G 63 56 °C F:CCAGAGATGTGGCCGGAAT biotin 
CHAT-rs1880676       R:CTCTTTCCCACTAGCTTCTCAAGG   
CHAT-rs1880676       seqR:CTGTGCTCAGTGCTTC   
PLAU-rs2227562 G>A 94 56 °C R:AGCTTCCCAGAAACCTTGTTACCA   
PLAU-rs2227562       F:CCCCTCAGGGAAGACTCAA biotin 
PLAU-rs2227562       seqF:TGGCCATAGCACAAGAGA   
PLAU-rs2227571 T>C 73 56 °C F:AGTGTTTTGACCTGAAAATGAGC biotin 
PLAU-rs2227571       R:CCTCAGTGCTCCCACCTCTA   
PLAU-rs2227571       seqR:CTGCAGTCTTCCCTTGA   
PLAU-rs4065 T>C 77 56 °C F:GGAAGATAGGCTCTGCACAGATG   
PLAU-rs4065       R:ATGCCTGAGGGTAAAGCTATTGT biotin 
PLAU-rs4065       seqF:GTGCCACCCACCAGG   
IDE7-rs2251101 T>C 130 60 °C F:AGATCGCACGACTGCACTGTAG biotin 
IDE7-rs2251101       R:TGAGTCCCTCCATGTATCATGAAT   
IDE7-rs2251101       seq:GGGGGACCTGCTG   
IDE8-rs551266 T>C 90 55 °C F:ACACTGCTAGGTACACGGCAAA   
IDE8-rs551266       R:TGAATCCAACTGCTAGATAAATTATAAGTAGG biotin 
IDE8-rs551266       seq:AATGCTCAATAAATGAGAGA   
IDE14-rs1832196 C>T 123 57 °C F:ATGTGACCATTTTGGGTTAGTG   
IDE14-rs1832196       R:CCATTTTGCCTAGGCTAGTCTCAA biotin 
IDE14-rs1832196       seq:TTGGCACGCTGTTG   
HHEX23-rs1544210 G>A 79 60 °C F:GGCCTGGGATTTTACTGTACTATCA biotin 
HHEX23-rs1544210       R:TTCCTGCATTTTGATTTTCTTCTTG   
HHEX23-rs1544210       seq:GCTACTGTTTTCCTGCA   
IGS6-rs967878 G>T 110 60 °C F:TGGTATCCGTGGGTTACAGACA biotin 
IGS6-rs967878       R:CCTGCTCCTGGGTTCTCCTTTCATC   
IGS6-rs967878       seq:ATCCAGGACTTGCTGA   
GSTO1-rs4925 C>A 107 60 °C F:TGTCTAGGTGCCATCCTTGGT biotin 
GSTO1-rs4925       R:TCCTCTAGCTTGGTAAATTCTTTACGA   
GSTO1-rs4925       seq:AATTCTTCTTTTAGGCCA     
GSTO2-rs2297235 G>A 68 58 °C F:ACTCTCGGGCTTCCAAATCTG   
GSTO2-rs2297235       R:GCGATCTGGAGCAGGAGCTA biotin 
GSTO2-rs2297235       seq:TGTCTCCCCAGGTTAA   
PRSS11-rs2293871 T>C 69 58 °C F:CATGTAAAGTCAGACCAGGAGGAA   
PRSS11-rs2293871       R:TGCAACACAAAGGGAAACACA biotin 
PRSS11-rs2293871       seq:CCAGGAGGAATGGAA   
18 
  
4.3. Statistical Analysis 
 
Allele frequencies for each polymorphic site were calculated by allele counting method. 
Goodness of fit to Hardy-Weinberg equilibrium was examined by chi square test.  Differences in 
genotype frequencies between patients and controls were tested by χ2 test.  Comparison of allele 
frequencies between patients and controls was performed by Z test.   Linkage disequilibrium 
between different polymorphic sites was tested as a function of the difference between observed 
and expected genotype frequencies.  Odd ratios (ORs) and corresponding 95% confidence 
intervals (CIs) were assessed for genotypes that significantly differed between cases and 
controls. Variables such as age (onset for cases, age for controls), sex and APOE carrier status 
were included as covariates in the model.  All analyses were performed using R 1.2.1 
(Gentleman and Ihaka, 1996) program.  Haplotype frequencies were estimated by EH program 
(Xie and Ott 1993).  The EH program implements expectation-maximization algorithm to 
estimate haplotype frequencies in unrelated individuals and applicable to case-control 
comparison. The mean AAO between different genotype groups were compared using one way 
analysis of variance (ANOVA) and adjusted for the effects of significant covariates such as sex 
and APOE. 
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5. Results 
 
5.1. Association of the APOE E2/E3/E4 Polymorphism with AD (Tables 6.1-6.3) 
 
The overall APOE genotype distribution differed significantly between cases and controls 
(p<0.0001) (Table  5.1).  The frequency of APOE*4 allele was 34.0 % in cases compared to 10. 
6 % in controls.  The age and sex adjusted odds ratio (OR) for developing AD with one 
(genotype 24, 34, 44) and two copies of APOE*4 (genotype 4/4) compared with no copies of 
APOE*4 (genotype 22, 23, 33) was 6.50 (95% CI: 5.20-8.15; p=0.0001) and 14.30 (95% CI:  
6.79-26.23; p=0.0001), respectively (Table 5.2).  These results are consistent with previous 
reports demonstrating a dose-dependent effect of APOE*4 on AD risk. 
Additionally, AAO was analyzed as a quantitative trait.  The mean AAO ± (SD) was 
72.36 ± 8.19 years for AD.  APOE showed strong association with AAO in AD APOE*4 carriers 
had significantly lower AAO than non-APOE*4 carriers (p=0.0001) (Table 5.3). 
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 Table 5.1 Distribution of APOE E2/E3/E4 Polymorphism  
APOE    
 AD Cases(1012)  Controls(771)   
  n (%)   n (%)   
33 374 0.37  502 0.65  
34 478 0.47  122 0.16  
23 37 0.06  112 0.15  
24 25 0.16  17 0.02  
44 92 0.76  12 0.02  
22 3 0.03  3 0.00  
       
3 0.63   0.81  p< 0.001 
4 0.34   0.11  p< 0.001 
2 0.03     0.09   p< 0.001 
       
 
 
Table 5.2 Sex Adjusted Age at Onset (Mean ± S.E.) Among APOE Genotype  
APOE Adjusted Age at Onset   
    
22 79.396±2.91  
23 72.137± 0.93  
24 73.373±1.04  
33 73.701±0.32  
34 71.13±0.27  
44 71.953±1.31  
 p-value over APOE < 0.0001  
        
 
Table 5.3 Sex Adjusted Age at Onset Among APOE*4 and non-APOE4*4 Carriers 
        
APOE Adjusted Age of Onset   
    
Non-E4 Carrier 73.608±0.31  
E4 Carrier 71.278±0.26  
 p-value over APOE < 0.0001  
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Table 5.4 Distribution of the CHAT/exon S/ D7N (rs1880676) Genotype and Allele Frequencies in AD Patients and 
Controls 
 
  AD Cases  Controls   
Genotype n %   n %    
         
AA  62 6.19  44 6.24   
AG  376 37.56  292 41.42   
GG  563 56.24  369 52.34   
         
Total  1001   705    
         
         
Allele frequency        
       p value  
A  0.250   0.270    
G  0.750   0.730  0.19  
                 
Age-sex and APOE adjusted OR      
         
   AA vs. AG+GG  0.98(0.65-1.47;p=0.90) 
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Table 5.5 Distribution of the CHAT/exon S/ D7N (rs1880676) Polymorphism Among APOE*4 and non-APOE*4 
Carriers 
 
  Genotype Frequency  Allele Frequency  
APOE*4 n AA AG GG A G  
 AD Cases 575 41 219 315   0.262 0.738  
 % 7.13 38.09 54.78     
         
Controls 144 10 56 78  0.264 0.736  
 % 6.94 38.89 54.17     
       p=0.99  
                
         
non-
APOE*4         
AD cases 407 19 152 236  0.233 0.767  
 % 4.67 37.35 57.99     
         
Controls 558 34 235 289  0.272 0.728  
 % 6.09 42.11 51.79     
       p=0.06  
                 
Age- and sex- adjusted OR       
     AA vs. AG+GG   
  APOE*4   0.97(0.47,2.01;p=0.94)  
  non- APOE*4  1.18(0.65,2.16;p=0.58)  
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Table 5.6 Sex and APOE Adjusted Age-at-Onset (Mean ± SE) Among CHAT/exonS/ D7N (rs1880676)  Genotype 
(late onset) 
 
 
 
  Genotype 
 AA AG GG 
Mean AAO 70.94±0.75 72.48±0.34 72.41±0.27 
sample size 57 340 495 
 p value= 0.25 
        
 
 
Table 5.7 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among CHAT/exonS/ D7N (rs1880676) Genotype 
(late and early onset) 
 
    
  Genotype 
 AA AG GG 
Mean AAO 69.20±0.88 70.33±0.44 70.17±0.37 
sample size 62 379 569 
 p value= 0.85 
    
 
 
 
Table 5.8 Summary of AAO Analysis CHAT/exonS/ D7N (rs1880676) 
 
  
AAO  
(late onset) 
AAO 
(late and early)  
Effect ANOVA p-value ANOVA p-value  
N 917 1037  
CHATrs1880676 Genotype 0.11 0.78  
APOE < 0.0001 < 0.0001  
Sex 0.08 0.01  
CHATrs1880676 Genotype* APOE 0.42 0.62  
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Table 5.9 Distribution of the CHAT/exon 5/A120T (rs3810950) Genotype and Allele Frequencies in AD Patients 
and Controls  
 
  AD  Cases  Controls   
Genotype n %   n %    
         
AA  60 6.01  49 6.92   
AG  377 37.74  296 41.81   
GG  562 56.26  363 51.27   
         
Total  999   708    
         
         
Allele frequency        
       p value  
A  0.249   0.278    
G  0.751   0.722  0.06  
                 
Age, sex and APOE adjusted OR      
         
   AA+AG vs. GG  0.98(0.79,1.22;p=0.10) 
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Table 5.10 Distribution of the CHAT/exon 5/A120T (rs3810950) Polymorphism Among APOE*4 and non-
APOE*4 Carriers 
 
        
  Genotype Frequency Allele Frequency 
APOE*4 n AA AG GG  A  G 
AD Cases 581 40 220 321  0.258 0.742 
 % 6.88 37.87 55.25    
        
Controls 141 10 55 76  0.266 0.734 
 % 7.09 39.01 53.90    
       p=0.79 
               
        
non-
APOE*4        
AD Cases  408 18 155 235  0.234 0.766 
 % 4.41 37.99 57.60    
        
Controls 566 39 240 287  0.281 0.719 
 % 6.89 42.40 50.71    
       p=0.02 
                
Age and sex adjusted OR      
     AA+AG vs. GG  
  APOE*4   1.0(0.69,1.46;p=0.99) 
  non- APOE*4  0.76(0.58,0.99;p=0.046) 
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Table 5.11 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the CHAT/exon 5/A120T (rs3810950) 
Genotype (late onset) 
 
  Genotype 
 AA AG GG 
Mean AAO 70.53±0.78 72.23±0.33 72.72±0.27 
sample size 54 350 520 
 p value= 0.08 
        
 
 
 
Table 5.12 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the CHAT/exon 5/A120T (rs3810950) 
Genotype (late and early onset) 
 
    
    
  Genotype 
 AA AG GG 
Mean AAO 69.29±0.95 70.13±0.45 70.39±0.36 
sample size 58 390 591 
 p value= 0.62 
        
 
 
 
Table 5.13 Summary of AAO Analysis the CHAT/exon 5/A120T (rs3810950) 
 
  
AAO  
(Late Onset) 
AAO  
(Early and Late) 
Effect ANOVA p-value ANOVA p-value 
N 924 1039 
CHATrs3810950 Genotype 0.035 0.62 
APOE < 0.0001 < 0.0001 
Sex 0.18 0.01 
CHATrs3810950 Genotype * APOE 0.31 0.52 
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Table 5.14 Distribution of the CHAT/intron9/11604 G→A (rs868750) Genotype and Allele Frequencies in AD 
Patients and Controls  
 
                
   AD Cases  Controls    
Genotype n %   n %    
         
AA  39 3.94  13 1.84   
GA  322 32.56  217 30.74   
GG  628 63.50  476 67.42   
         
Total  989   706    
         
         
Allele frequency        
       p value  
A  0.202   0.172    
G  0.798   0.828  0.03  
                 
Age, sex and APOE adjusted OR      
         
   AA vs. GA+GG  2.37(1.19-4.73;p=0.007) 
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Table 5.15 Distribution of the CHAT/intron9/11604 G→A (rs868750) Polymorphism Among APOE*4 and non-
APOE*4 Carriers 
 
        
  Genotype Frequency Allele Frequency 
APOE*4 n AA GA GG  A G 
AD Cases 579 19 190 370  0.197 0.803 
 % 3.28 32.82 63.90    
        
Controls 140 3 49 88  0.196 0.804 
 % 2.14 35.00 62.86    
       p=0.97 
               
        
non-
APOE*4        
AD Cases  401 20 131 250  0.213 0.787 
 % 4.99 32.67 62.34    
        
Controls 565 10 168 387  0.166 0.834 
 % 1.77 29.73 68.50    
       p=0.006 
                
Age and sex adjusted OR      
     AA vs. GA+GG  
  APOE*4   1.33(0.38,4.59;p=0.65) 
  non- APOE*4  2.94(1.33,6.51;p=0.007) 
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Table 5.16 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the CHAT/intron9/11604 G→A (rs868750) 
Genotype (late onset) 
 
 
  Genotype 
 AA GA GG 
Mean AAO 73.56±0.99 72.71±0.37 71.95±0.26 
sample size 31 285 565 
 p-value= 0.77 
    
 
 
 
Table 5.17 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the CHAT/intron9/11604 G→A (rs868750) 
Genotype (late and early onset) 
 
 
 
  Genotype 
 AA GA GG 
Mean AAO 71.62±1.13 70.27±0.37 69.94±0.25 
sample size 35 292 573 
 p-value= 0.89 
    
 
 
 
Table 5.18 Summary of AAO Analysis CHAT/intron9/11604 G→A (rs868750)     
 
  
AAO 
(late onset) 
AAO 
(late and early onset) 
Effect ANOVA p-value ANOVA p-value 
N 917 1033 
CHATrs8687650 Genotype 0.79 0.90 
APOE < 0.0001 < 0.0001 
Sex 0.18 0.18 
CHATrs8687650 Genotype * APOE 0.48 0.17 
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Table 5.19 Estimated 3-site CHAT Haplotype Distribution in AD cases and Controls Using the EH Method 
 
Haplotype             
rs1880676 rs3810950 rs8687650 Total AD C Z 
p 
value Effect 
A A A 0.0052 0.0030 0.0081 1.859 0.0630  
A A G 0.0000 0.0001 0.0000 0.405 0.6856  
A G A 0.5566 0.5570 0.5558 0.067 0.9465  
A G G 0.1796 0.1901 0.1650 1.860 0.0629  
G A A 0.2448 0.2343 0.2600 1.677 0.0936  
G A G 0.0107 0.0128 0.0073 1.613 0.1068  
G G A 0.0029 0.0022 0.0037 0.765 0.4443  
G G G 0.0002 0.0004 0.0000 0.878 0.3799  
   1640 961 679    
     Ln(L) 2757.64 1617.72 1134.21 0.12a   
a Calculated from the T5 statistic: 2[ln(L)case + ln(L)control - ln(L) case+control] ; df=7 
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 5.2. 
5.3. 
Distribution of CHAT/exon S/D7N (rs1880676) Polymorphism in AD Cases 
and Controls (Tables 5.4- 5.5) 
 
The overall distribution pattern of genotype and allele frequencies of the CHAT/exon S/ 
D7N/A→G transition was similar between cases and controls (Table 5.4). The age-, sex-, and 
APOE-adjusted OR of developing AD was 0.98(95% CI: 0.65-1.47; p=0.90).  There was no 
significant difference in CHAT genotype or allele distribution among either APOE*4 carriers or 
non-APOE4 carriers (table 5.5). 
 
Distribution of CHAT/ exon 5/A120T (rs3810950) Polymorphism in AD 
Cases and Controls (Table 5.9-5.10) 
 
There was no significant difference in genotype (p=0.10) or allele (0.06) distribution among AD 
cases and controls for CHAT/exon 5/A→G transition (Table 5.9).  The OR for developing AD 
for individuals carrying A allele (AA+AG vs. GG) was 0.98(95% CI: 0.79, 1.22; p=0.10) after 
adjusting for effects of age, sex and APOE.  However, when the sample was stratified by APOE 
status, the A allele of CHAT/A120T was associated with protective effect among non-APOE*4 
carriers in both genotype (p= 0.046) or allele (p=0.02) distribution.  The age and sex adjusted OR 
was among non-APOE*4 carriers with A allele was 0.76(0.58, 0.99; p=0.046) (Table 5.10).  This 
indicates that exon 5/A allele has a modest protective effect against developing AD. 
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 5.4. 
5.5. 
Distribution of CHAT/intron 9, 11604 G→A (rs868750) Polymorphism in AD 
Cases and Controls (Table 5.14-5.15) 
 
The CHAT/intron 9 polymorphism showed a significant difference in both allele (p=0.03) and 
genotype (p=0.007) frequencies between cases and controls.  The frequencies of the AA 
genotype was significantly higher in AD patients compared to controls (p=0.007).  The age, sex 
and APOE adjusted OR for (AA vs. AG+GG) was 2.37(95% CI: 1.19-4.73; p=0.007) (Table 
5.14). However, stratification of data by APOE genotype revealed that association was confined 
among non-APOE*4 carriers only; genotype (p=0.007) and allele (p=0.006).  The age, sex and 
APOE adjusted OR among the non-APOE*4 carriers (AA vs. AG+GG) was 2.94(95% CI, 1.33, 
6.51; p=0.007) and among APOE*4 carriers, it was 1.33(95% CI: 0.38, 4.59; p=0.65) (Table 
5.15).  This suggests that the association observed in total sample was attributed to non-APOE*4 
carriers.  It should be noted that the controls have slight deviation from HWE (p=0.04)   
Repeating genotypes in the control samples revealed the same results, suggesting the deviation 
from HWE is not attributable to the genotyping error.  When we checked the HWE within 
APOE*4 carriers (p=0.20) and non-APOE*4 carriers (p=0.09) they were in HWE.   
 
Three-site CHAT Haplotype Distribution in AD Cases and Controls (Table 
5.19) 
 
The 3-site CHAT haplotype distribution in AD cases and controls is presented in table 5.19.  We 
observed three major haplotypes (haplotypes AGA, AGG, GAA), which accounted for 98% of 
all possible marker combinations in AD cases, and 97% in the control sample.  No evidence for 
association with AD risk was provided by individual haplotype tests.  Likewise, the examination 
33 
 of the distribution differences in overall haplotype showed no significant association between 
case and control subjects (p=0.12).  
 
5.6. Sex- and APOE-Adjusted Age-At-Onset Among CHAT Genotypes (5.6-5.8, 
5.11- 5.13, 5.7.16-5.18) 
 
AAO was analyzed as a quantitative trait.  Mean AAO was 72.29 ±0.201 in LOAD and 
70.05±0.263 in all AD patients.  Genotypic association study for AAO effect in AD revealed no 
association for CHAT gene: exon S, exon 5, and intron 9 polymorphisms p=0.25, 0.08, 0.77, 
respectively, after adjusting for the effects of gender and APOE (Table 7.10).  Logistic 
regression analysis to determine possible interaction between APOE and CHAT: exon S, exon 5, 
and intron 9 polymorphism revealed no interaction (p=0.62, 0.52, 0.17, respectively) (Tables: 
5.8, 5.13, 5.18). 
34 
  
 
 
 
Table 5.20 Distribution of the PLAU/intron5/G→A (rs2227562) Genotype and Allele Frequencies in AD Patients 
and Controls  
 
  AD Cases  Controls   
Genotype n %   n %    
         
AA  20 2.48  21 3.17   
GA  187 23.17  166 25.04   
GG  600 74.35  476 71.79   
         
Total  807   663    
         
         
Allele frequency        
       p value  
A  0.141   0.157    
G  0.859   0.843  0.23  
                 
Age, sex and APOE adjusted OR      
         
   AA vs. GA+GG  0.80(0.40-1.62;p=0.54) 
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Table 5.21 Distribution of the PLAU/intron5/G→A (rs2227562) Polymorphism Among APOE*4 and non-APOE*4 
Carriers 
 
        
  Genotype Frequency Allele Frequency 
APOE*4 n AA GA GG  A G 
AD Cases 469 14 110 345  0.147 0.853 
 % 2.99 23.45 73.56    
        
Controls 129 2 36 91  0.155 0.845 
 % 1.55 27.91 70.54    
       p=0.75 
               
        
non-
APOE*4        
AD Cases 330 6 75 249  0.132 0.868 
 % 1.82 22.73 75.45    
        
Controls 531 18 130 383  0.156 0.844 
 % 3.39 24.48 72.13    
       p=0.16 
                
Age and sex adjusted OR      
     AA vs. GA+GG  
  APOE*4   1.96(0.44,8.81;p=0.38) 
  non- APOE*4  0.53(0.20,1.37;p=0.19) 
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Table 5.22 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the PLAU/intron5/G→A (rs2227562) (late 
onset) 
 
 
  Genotype 
 TT CT CC 
Mean AAO 71.62±1.13 70.27±0.37 69.94±0.25 
sample size 35 292 573 
 p-value= 0.89 
    
 
 
 
Table 5.23 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the PLAU/intron5/G→A (rs2227562)  
Genotype (early and late onset) 
 
 
 
  Genotype 
 AA GA GG 
Mean AAO 70.56±1.77 70.30±0.57 70.00±0.35 
sample size 19 185 610 
 p value= 0.96 
        
 
 
 
Table 5.24 Summary of AAO Analysis PLAU/intron5/G→A (rs2227562) 
 
  
AAO  
(late onset) 
AAO  
(early + late) 
Effect ANOVA p-value ANOVA p value 
N 741 846 
PLAU rs3855 Genotype 0.81 0.98 
APOE < 0.0001 < 0.0001 
Sex 0.05 0.01 
PLAU rs3855 Genotype * APOE 0.79 0.82 
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Table 5.25 Distribution of the PLAU/intron9/T→C (rs2227571) Genotype and Allele Frequencies in AD Patients 
and Controls 
 
  AD  Cases  Controls   
Genotype n %   n %    
         
CC  184 18.40  147 21.09   
CT  485 48.50  328 47.06   
TT  331 33.10  222 31.85   
         
Total  1000   697    
         
         
Allele frequency        
       p value  
C  0.427   0.446    
T  0.574   0.554  0.27  
                 
Age, sex and APOE adjusted OR      
         
   CC vs. CT+TT  0.84(0.64-1.10;p=0.21) 
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Table 5.26 Distribution of the PLAU/intron9/T→C (rs2227571) Polymorphism Among APOE*4 and non-APOE*4 
Carriers 
 
        
  Genotype Frequency Allele Frequency 
APOE*4 n CC CT TT  C T 
AD Cases 575 104 286 185  0.430 0.570 
 % 18.09 49.74 32.17    
        
Controls 143 33 69 41  0.472 0.528 
 % 23.08 48.25 28.67    
       p=0.20 
               
        
non-
APOE*4        
AD Cases 407 77 190 140  0.423 0.577 
 % 18.92 46.68 34.40    
        
Controls 551 113 258 180  0.439 0.561 
 % 20.51 46.82 32.67    
       p=0.63 
                
Age and sex adjusted OR      
     CC vs. CT+TT  
  APOE*4   0.71(0.45,1.11;p=0.14) 
  non- APOE*4  0.93(0.66,1.30;p=0.66) 
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Table 5.27 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the PLAU/intron9/T→C (rs2227571) (late 
onset) 
 
 
  Genotype 
 CC CT TT 
Mean AAO 72.96±0.46 72.27±0.30 72.23±0.35 
sample size 163 433 297 
 p value= 0.043 (0.01)* 
        
*p value for (CC+CT vs. TT)   
 
 
 
 
Table 5.28 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the PLAU/intron9/T→C (rs2227571) (early 
and late onset) 
 
 
  Genotype 
 CC CT TT 
Mean AAO 70.20±0.63 70.43±0.39 69.77±0.48 
sample size 189 488 335 
 p value= 0.42 
        
 
 
 
Table 5.29 Summary of AAO Analysis PLAU/intron9/T→C (rs2227571) 
 
  
AAO 
(late onset) 
AAO 
(early and late) 
Effect ANOVA p value ANOVA p value 
N 917 1038 
PLAUrs5634 Genotype 0.043* 0.42 
APOE < 0.0001 < 0.0001 
Sex 0.10 0.02 
PLAUrs5634 Genotype * APOE 0.44 0.88 
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Table 5.30 Distribution of the PLAU/3’UTR/T→C (rs4065) Genotype and Allele Frequencies in AD Patients and 
Controls 
 
  AD  Cases  Controls    
Genotype n %   n %    
         
CC  149 15.07  131 18.99   
TC  476 48.13  320 46.38   
TT  364 36.80  239 34.64   
         
Total  989   690    
         
         
Allele frequency        
       p value  
C  0.391   0.422    
T  0.609   0.578  0.07  
                 
Age, sex and APOE adjusted OR      
         
   CC vs. TC+TT  0.71(0.53-0.95;p=0.02) 
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Table 5.31 Distribution of the PLAU/3’UTR/T→C (rs4065) Polymorphism Among APOE*4 and non-APOE*4 
Carriers 
 
        
    Genotype Frequency Allele Frequency 
APOE*4 n CC TC TT  C T 
AD Cases  572 87 279 206  0.396 0.604 
 % 15.21 48.78 36.01    
        
Controls 139 32 64 43  0.460 0.540 
 % 23.02 46.04 30.94    
       p=0.04 
               
        
non-
APOE*4        
AD Cases 399 59 189 151  0.385 0.615 
 % 14.79 47.37 37.84    
        
Controls 548 98 256 194  0.412 0.588 
 % 17.88 46.72 35.40    
       p=0.19 
               
Age and sex adjusted OR      
     CC vs. TC+TT  
  APOE*4   0.58(0.36,0.92;p=0.02) 
  non- APOE*4  0.82(0.57,1.18;p=0.28) 
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Table 5.32 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the PLAU/3’UTR/T→C (rs4065) 
Polymorphism (late onset) 
 
 
  Genotype 
 CC CT TT 
Mean AAO 70.97±0.48 72.33±0.31 72.14±0.34 
sample size 131 423 328 
 p value= 0.10 (0.036)* 
        
*p value for (CC+CT vs. TT)   
 
 
 
Table 5.33 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the PLAU/3’UTR/T→C (rs4065) 
Polymorphism (early and late onset) 
 
  
  Genotype  
 CC CT TT  
Mean AAO 69.85±0.71 70.56±0.39 69.74±0.46  
sample size 155 474 371  
 p value= 0.51  
         
     
 
 
 
Table 5.34 Summary of AAO Analysis PLAU/3’UTR/T→C (rs4065)  
 
  
AAO 
(late onset) 
AAO 
(early and late) 
Effect ANOVA p value ANOVA p value 
N 906 1026 
PLAU/3’UTR Polymorphism 0.12 0.62 
APOE < 0.0001 < 0.0001 
Sex 0.08 0.01 
PLAU/3’UTR Polymorphism * APOE 0.48 0.41 
 
43 
  
 
 
 
Table 5.35 PLAU Haplotype Distribution in AD Cases and Controls 
 
Haplotype             
rs3855 rs5634 rs7338 Total AD C Z p′ Effect 
A C C 0.000 0.000 0.000    
A C T 0.002 0.003 0.002 0.613 0.5400  
A T C 0.145 0.138 0.153 1.104 0.2694  
A T T 0.256 0.251 0.263 0.740 0.4595  
G C C 0.003 0.003 0.003 0.292 0.7704  
G C T 0.564 0.577 0.551 1.357 0.1747  
G T C 0.002 0.002 0.003 0.876 0.3813  
G T T 0.028 0.027 0.025 0.398 0.6909  
   1399 774 625    
     ln(L) -2472.36 -1346.76 -1123.88 0.84a   
a Calculated from the T5 statistic: 2[ln(L)case + ln(L)control - ln(L) case+control] ; df=7 
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5.7. 
5.8. 
Distribution of the PLAU/intron5/G→A (rs2227562) Genotype and Allele 
Frequencies in AD Patients and Controls (Tables 5.20-5.21) 
 
The genotype and allele distribution of G→A at intron 5 in PLAU gene were similar between 
cases and controls (Table 5.20).  The OR for AA genotype was 0.80(95% CI: 0.40-1.62; p=0.54) 
after adjusting for the effect of age, sex and APOE.  There was no difference in genotype or 
allele frequencies among APOE*4 carriers (p=0.20) and non-APOE*4 carriers (p=0.63) (Table 
5.21).    
 
Distribution of the PLAU/intron9/T→C (rs2227571) Genotype and Allele 
Frequencies in AD Patients and Controls (Tables 5.25-5.26) 
 
The overall genotype frequency was comparable between cases and controls (p=0.21).   The OR 
for developing AD was 0.84(95% CI: 0.64-1.10; p=0.21) for intron 9 C carriers (TT vs. CT+CC) 
compared to non-C carriers after adjusting for age, sex and APOE (Table 5.25).  When the data 
were stratified by APOE status, the results did not change (Table 5.26).   The age-, sex-, and 
APOE adjusted OR for C allele carriers was 0.71(95% CI: 0.45, 1.11; p=0.14) for APOE*4 
carriers and 0.93(95% CI: 0.66, 1.30; p=0.66) for non-APOE*4 carriers (Table 5.26). 
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 5.9. 
5.10. 
Distribution of the PLAU/3’UTR/T→C (rs4065) Genotype and Allele 
Frequencies in AD Patients and Controls (Tables 5.30-5.31) 
 
There was a borderline difference in allele distribution between cases and controls for the PLAU 
3’ UTR polymorphism in the total sample (39.1 % vs. 42.2 %; p=0.07; Table 5.30). The age, sex, 
and APOE adjusted OR between the CC and other genotypes 0.71(95% CI 0.53-0.95; p=0.02).  
Further stratification of data by APOE status showed that the association between PLAU and AD 
was confined to APOE*4 carriers only (p=0.02).  The age-, sex- adjusted OR among APOE*4 
carriers was 0.58(95% CI: 0.36, 0.92; p=0.02; Table 5.31).  This suggests that the effect seen in 
the total sample was from APOE*4 carriers.   
 
Three-site PLAU Haplotype Distribution in AD Cases and Controls (Table 
5.35) 
 
Table 5.35 demonstrates the frequencies for the estimated three-site haplotypes among AD cases 
and control subjects.  There were three major haplotypes:  ATC, ATT, and GCT, which 
represents for 96% of all possible marker combinations in AD and control sample. Haplotype 
ACC was not present in either AD cases or controls samples. The remaining haplotypes were 
less than 1% with the exception of GTT haplotype, which is less than 3 %.  Individual haplotype 
tests reveal no evidence of association with AD risk.  Likewise, the examination of the 
distribution differences in overall haplotype showed no significant association between PLAU 
haplotypes using case and control subjects (p=0.84).  
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 5.11. Sex- and APOE-Adjusted Age-at-Onset Among PLAU Genotypes (5.22-5.23, 
5.27-5.28, 5.32-5.33) 
 
The mean age at onset was 72.29 ±0.201 years for LOAD (range between 60-91 years) and 
70.05±0.263 years in the total AD sample (range between 33-91 years).  There was a significant 
difference in AAO among the intron 9 genotypes (p=0.04) after adjusting for sex and age.  When 
we grouped the data, C carriers (CC+CT) vs. TT, the difference in AAO between genotypes 
became more significant (p=0.01) (Table 5.27).  As LOAD is complex and heterogeneous 
disorder, we look for possible interaction between APOE and 3 PLAU polymorphisms.  Logistic 
regression analysis of APOE and 3 PLAU: intron 5, intron 9, and 3’ UTR polymorphisms 
revealed no interaction (p= 0.79, 0.44, and 0.48, respectively) (Tables: 5.24, 5.29, and 5.34). 
9 polymorphism revealed no interaction (p=0.62, 0.52, and 0.17, respectively) (Tables: 5.8, 5.13, 
5.18). 
47 
  
 
 
Table 5.36 Distribution of the IGS6/G→T (rs967878) Genotype and Allele Frequencies in AD Patients and 
Controls 
 
  AD Cases  Controls    
Genotype n %   n %    
         
TT  161 17.69  109 14.65   
GT  458 50.33  374 50.27   
GG  291 31.98  261 35.08   
         
Total  910   744    
         
         
Allele frequency        
       p value  
T  0.429   0.398    
G  0.571   0.602  0.07  
                 
Age, sex and APOE adjusted OR      
         
   TT vs. GT+GG  1.29 (0.96-1.32;p=0.09) 
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Table 5.37 Distribution of the IGS6/G→T (rs967878) Polymorphism Among APOE*4 and non-APOE*4 Carriers 
 
        
     Genotype Frequency Allele Frequency 
APOE*4 n  A C TT GT GG 
534 AD Cases  94 263 177  0.422 0.578 
 % 17.60 49.25 33.15    
        
142 Controls 22 79 41  0.433 0.567 
 % 15.49 55.63 28.87    
       p=0.90 
               
        
non-
APOE*4        
371 AD Cases  67 191 113  0.438 0.562 
 % 18.06 51.48 30.46    
        
599 Controls 87 293 219  0.390 0.610 
 % 14.52 48.91 36.56    
       p=0.04 
               
Age and sex adjusted OR      
     TT vs. GT+GG  
  APOE*4   1.20(0.72,2.00;p=0.49) 
  non- APOE*4  1.34(0.93,1.92;p=0.12) 
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Table 5.38 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the IGS6/G→T (rs967878) Polymorphism 
(late onset) 
 
 
  Genotype 
 CC CT TT 
Mean AAO 72.79±0.51 72.54±0.31 72.11±0.38 
sample size 149 421 261 
 p-value= 0.52 
        
 
 
 
Table 5.39 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the IGS6/G→T (rs967878) Polymorphism 
(early and late onset) 
 
 
  Genotype 
 CC CT TT 
Mean AAO 70.20±0.72 70.36±0.39 70.05±0.55 
sample size 154 459 284 
 p-value= 0.33 
        
 
 
 
Table 5.40 Summary of AAO Analysis IGS6/G→T (rs967878) 
 
  
AAO 
(late onset) 
AAO 
(early and late onset) 
Effect ANOVA p value ANOVA p value 
N 845 943 
IGS6 Genotype 0.52 0.33 
APOE < 0.0001 < 0.0001 
Sex 0.14 0.03 
IGS6 Genotype * APOE 0.97 0.44 
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Table 5.41 Distribution of the IDE7/T→C (rs2251101) Genotype and Allele Frequencies in AD Patients and 
Controls 
 
   AD Cases  Controls   
Genotype n %   n %    
         
CC  102 10.56  68 9.29   
CT  384 39.75  291 39.75   
TT  480 49.69  373 50.96   
         
Total  966   732    
         
         
Allele frequency        
       p value  
C  0.304   0.292    
T  0.696   0.708  0.45  
                 
Age, sex and APOE adjusted OR      
         
   CC vs. CT+TT  1.20(0.83-1.71;p=0.33) 
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Table 5.42 Distribution of the IDE7/T→C (rs2251101) Polymorphism Among APOE*4 and non-APOE*4 Carriers 
 
        
        
   Genotype Frequency Allele Frequency  
APOE*4 n CC CT TT  C T  
AD Cases  559 59 221 279  0.303 0.697  
 % 10.55 39.53 49.91     
         
Controls 149 17 63 69  0.326 0.674  
 % 11.41 42.28 46.31     
       p=0.39  
                
         
non-
APOE*4         
AD Cases 390 43 158 189  0.313 0.687  
 % 11.03 40.51 48.46     
         
Controls 580 51 226 303  0.283 0.717  
 % 8.79 38.97 52.24     
       p=0.16  
                
Age and sex adjusted OR       
     CC vs. CT+TT   
  APOE*4   0.92(0.52,1.64;p=0.78)  
  non- APOE*4  1.40(0.90,2.19;p=0.14)  
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Table 5.43 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the IDE7/T→C (rs2251101) Polymorphism 
(late onset) 
 
 
  Genotype 
 CC CT TT 
Mean AAO 72.65±0.60 72.05±0.32 72.54±0.30 
sample size 97 356 446 
 p-value= 0.63 
        
 
 
 
Table 5.44 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the IDE7/T→C (rs2251101) Polymorphism 
(early and late Onset) 
 
 
  Genotype 
 CC CT TT 
Mean AAO 70.12±0.94 70.19±0.40 70.25±0.40 
sample size 101 406 503 
 p-value= 0.38 
        
 
 
 
Table 5.45 Summary of AAO Analysis IDE7/T→C (rs2251101) 
 
  
AAO 
(late onset) 
AAO 
(early and late) 
Effect ANOVA p-value ANOVA p value 
N 896 1037 
IDE7 Genotype 0.63 0.38 
APOE < 0.0001 < 0.0001 
Sex 0.16 0.03 
IDE7 Genotype * APOE 0.79 0.89 
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Table 5.46 Distribution of the IDE8/T→C (rs551266) Genotype and Allele Frequencies in AD Patients and 
Controls 
 
  AD  Cases  Controls    
Genotype n %   n %    
         
CC  27 3.10  16 2.37   
TC  269 30.88  189 28.04   
TT  575 66.02  469 69.58   
         
Total  871   674    
         
         
Allele frequency        
       p value  
C  0.185   0.164    
T  0.815   0.836  0.13  
                 
Age, sex and APOE adjusted OR      
         
   CC v. TC+TT  1.38(0.68-2.80;p=0.37) 
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Table 5.47 Distribution of the IDE8/T→C (rs551266) Polymorphism Among APOE*4 and non-APOE*4 Carriers 
 
    Genotype Frequency Allele Frequency 
APOE*4 n CC TC TT C T 
AD Cases 509 18 165 326  0.197 0.803 
 % 3.54 32.42 64.05    
        
Controls 137 3 46 88  0.190 0.810 
 % 2.19 33.58 64.23    
       p=0.79 
               
        
non-
APOE*4        
AD Cases 354 9 103 242  0.171 0.829 
 % 2.54 29.10 68.36    
        
Controls 534 13 143 378  0.158 0.842 
 % 2.43 26.78 70.79    
       p=0.26 
               
Age and sex adjusted OR      
     CC vs. TC+TT  
  APOE*4   1.72(0.50,5.97;p=0.39) 
  non- APOE*4  1.23(0.50,3.05;p=0.65) 
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Table 5.48 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the IDE8/T→C (rs551266) Polymorphism 
(late onset) 
 
 
  Genotype 
 CC CT TT 
Mean AAO 73.15±1.02 72.16±0.39 72.83±0.27 
sample size 26 233 516 
 p-value= 0.35 
        
 
 
 
Table 5.49 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the IDE8/T→C (rs551266) Polymorphism 
(early and late onset) 
 
 
  Genotype 
 CC CT TT 
Mean AAO 68.620±2.19 70.22±0.51 70.61±0.35 
sample size 26 259 580 
 p-value= 0.78 
        
 
 
 
Table 5.50 Summary of AAO Analysis IDE8/T→C (rs551266) 
 
  
AAO 
(late onset) 
AAO 
(early and late) 
Effect ANOVA p value ANOVA p value 
N 818 913 
IDE8 Genotype 0.35 0.78 
APOE < 0.0001 < 0.0001 
Sex 0.18 0.14 
IDE8 Genotype * APOE 0.71 0.97 
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Table 5.51Distribution of the IDE14/C→T (rs1832196) Genotype and Allele Frequencies in AD Patients and 
Controls 
 
  
  AD  Cases  Controls   
Genotype n %   n %    
         
TT  18 1.78  12 1.72   
TC  244 24.11  164 23.50   
CC  750 74.11  522 74.79   
         
Total  1012   698    
         
         
Allele frequency        
       p value  
T  0.138   0.135    
C  0.862   0.865  0.8  
                 
Age, sex and APOE adjusted OR      
         
   TT vs. TC+CC  1.24(0.55-2.82;p=0.60) 
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Table 5.52 Distribution of the IDE14/C→T (rs1832196) Polymorphism Among APOE*4 and non-APOE*4 
Carriers 
 
  IDE 14 C→T Genotype Allele Frequency 
APOE*4 n TT TC CC  T C 
AD Cases 594 11 138 445  0.135 0.865 
 % 1.85 23.23 74.92    
        
Controls 143 1 37 105  0.136 0.864 
 % 0.70 25.87 73.43    
       p=0.97 
               
        
non-
APOE*4        
AD Cases 413 7 106 300  0.145 0.855 
 % 1.69 25.67 72.64    
        
Controls 554 11 127 416  0.134 0.866 
 % 1.99 22.92 75.09    
       p=0.49 
                
Age and sex adjusted OR      
     TT vs. TC+CC  
  APOE*4   2.96(0.38,23.27;p=0.30) 
  non- APOE*4  0.96(0.35,2.60;p=0.94) 
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Table 5.53 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the IDE14/C→T (rs1832196) 
Polymorphism (late onset) 
 
 
  Genotype 
 TT TC CC 
Mean AAO 72.85±1.91 72.51±0.38 71.31±0.24 
sample size 16 220 665 
 p-value= 0.55 
        
 
 
 
Table 5.54 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the IDE14/C→T (rs1832196) 
Polymorphism (early and late onset) 
 
 
  Genotype 
 TT TC CC 
Mean AAO 71.11±2.32 70.21±0.53 70.09±0.32 
sample size 35 292 573 
 p-value= 0.62 
        
 
 
 
Table 5.55 Summary of AAO Analysis IDE14/C→T (rs1832196) 
 
  
AAO 
(late onset) 
AAO 
(early and late) 
Effect ANOVA p-value ANOVA p-value 
N 938 1060 
IDE14 Genotype 0.55 0.62 
APOE < 0.0001 < 0.0001 
Sex 0.04 0.01 
IDE14 Genotype * APOE 0.9 0.32 
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Table 5.56 Distribution of the HHEX/G→A (rs1544210) Genotype and Allele Frequencies in AD Patients and 
Controls 
 
  AD Cases  Controls  
Genotype n %   n %    
         
AA  218 24.44  189 24.51   
GA  440 49.33  380 49.29   
GG  234 26.23  202 26.20   
         
Total  892   771    
         
         
Allele frequency        
       p value  
A  0.491   0.492    
G  0.509   0.508  0.95  
                 
Age, sex and APOE adjusted OR      
         
   AA vs. GA+GG  0.90(0.70-1.16;p=0.43) 
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Table 5.57 Distribution of the HHEX/G→A (rs1544210) Polymorphism Among APOE*4 and non-APOE*4 
Carriers 
 
        
   Genotype Frequency Allele Frequency 
APOE*4 n AA GA GG  A G 
AD Cases 516 136 255 125  0.511 0.489 
 % 26.36 49.42 24.22    
        
Controls 151 36 77 38  0.493 0.507 
 % 23.84 50.99 25.17    
       p=0.54 
               
        
non-
APOE*4        
AD Cases 368 77 184 107  0.459 0.541 
 % 20.92 50.00 29.08    
        
Controls 617 152 302 163  0.491 0.509 
 % 24.64 48.95 26.42    
       p=0.17 
                
Age and sex adjusted OR      
     AA vs. AG+GG  
  APOE*4   1.10(0.72-1.69;p=0.65) 
  non- APOE*4  0.81(0.59,1.11;p=0.19) 
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Table 5.58 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the HHEX/G→A (rs1544210) 
Polymorphism (late onset) 
 
 
  Genotype 
 AA GA GG 
Mean AAO 71.48±0.48 72.68±0.30 73.04±0.43 
sample size 190 396 206 
 p-value= 0.07 
        
 
 
 
Table 5.59 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the HHEX G→A (rs1544210) 
Polymorphism (early and late onset) 
 
 
  Genotype 
 AA GA GG 
Mean AAO 68.55±0.67 70.93±0.38 70.45±0.59 
sample size 211 444 239 
 p-value= 0.83 
        
 
 
 
Table 5.60 Summary of AAO Analysis HHEX G→A (rs1544210) 
 
  
AAO 
(late onset) 
AAO 
(early and late) 
Effect ANOVA p value ANOVA p value 
N 836 944 
HHEX Genotype 0.07 0.83 
APOE < 0.0001 < 0.0001 
Sex 0.15 0.01 
HHEX Genotype * APOE 0.63 0.72 
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Table 5.61 Estimated 5-site IDE-HHEX-IGS6 Haplotype Distribution in AD Cases and Control Using the EH 
Method 
 
H 
ID  IDE7 IDE8 IEE14 HHEX IGS6 Total AD C Z p′ Effect 
H1 A C C C A 0 0 0    
H2 A C C C C 0 0 0    
H3 A C C T A 0.000003 0 0.001833 1.493 0.1354  
H4 A C C T C 0.002128 0.00238 0.000043 1.792 0.0731  
H5 A C T C A 0 0 0    
H6 A C T C C 0 0 0    
H7 A C T T A 0 0 0    
H8 A C T T C 0 0 0    
H9 A T C C A 0.17118 0.167966 0.176602 0.585 0.5584  
H10 A T C C C 0.160786 0.160038 0.163385 0.233 0.8160  
H11 A T C T A 0.070288 0.062132 0.075689 1.366 0.1719  
H12 A T C T C 0.178983 0.180278 0.180764 0.032 0.9742  
H13 A T T C A 0.079571 0.090121 0.066259 2.291 0.0220 Risk 
H14 A T T C C 0.008564 0.000151 0.016027 4.387 < 0.0001 Protective 
H15 A T T T A 0.016993 0.014391 0.020738 1.229 0.2191  
H16 G T T T C 0.023624 0.02591 0.021066 0.822 0.4108  
H17 G C C C A 0.000772 0.001207 0.000001 1.311 0.1899  
H18 G C C C C 0.006245 0.00665 0.006094 0.179 0.8577  
H19 G C C T A 0.023394 0.024547 0.02311 0.242 0.8091  
H20 G C C T C 0.139246 0.146317 0.12857 1.323 0.1858  
H21 G C T C A 0.000601 0.001168 0 1.291 0.1966  
H22 G C T C C 0.000005 0 0    
H23 G C T T A 0.000002 0 0.000001 0.035 0.9722  
H24 G C T T C 0.002983 0.002163 0.005092 1.228 0.2193  
H25 G T C C A 0.049163 0.052149 0.044332 0.937 0.3486  
H26 G T C C C 0.040567 0.04085 0.040557 0.038 0.9697  
H27 G T C T A 0.002048 
0.021107 0.014469 0.027224 2.261 0.0237 Protective 
H29 G T T C A 0 0 0    
H30 G T T C C 0.001108 0.002141 0.000746 0.960 0.3371  
H31 G T T T A 0 0 0    
H32 G T T T C 0.000639 0 0.001866 1.507 0.1319  
     n 1320 713 607    
         ln(L) -4886.3900 -2621.02 -2251.19  0.60  
0.004973 0.000001 2.669 0.0076 Risk 
H28 G T C T C 
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       5.12.    Distribution of the IGS6/G→T (rs967878) Genotype and Allele Frequencies in AD 
Patients and Controls (5.36-5.37) 
 
The overall genotype distribution of the IGS6 G→T polymorphism was similar between cases 
and controls (p=0.09) (Table 5.36).  The allele frequency of the A allele was similar in both cases 
and controls as well (p=0.07).  The age-, sex-, and APOE adjusted OR for IGS6/TT genotype vs. 
TG+GG genotypes was 1.29(95% CI: 0.96-1.32; p=0.09) (Table 5.36).  When stratifying the data 
by APOE status, there was no statistically significant difference in genotype or allele distribution 
among APOE*4 carriers (Table 5.37).  Among non-APOE*4 carriers, despite the fact that 
genotype frequency was not different between cases and controls (p=0.12) (Table 5.37), there 
was marginally significant differences in allele distribution between cases and controls (p=0.04).  
The OR for TT genotype vs. TG+ GG was 1.20 (95% CI: 0.72, 2.00; p=0.49) and 1.34 (95% CI: 
0.93, 1.92; p=0.12) for APOE*4 carriers and non-APOE*4 carriers, respectively. 
 
5.13. Distribution of the IDE7/T→C (rs2251101) Genotype and Allele Frequencies 
in AD Patients and Controls (5.41-5.42) 
 
The overall genotype and allele frequencies were similar among cases and controls for T→C 
transition in the IDE gene (Table 5.41).  The OR for CC genotype vs. TC+TT (T allele carriers) 
was 1.38 (95% CI: 0.68-2.80; p=0.37) after adjusting for sex, age and APOE.  Stratification of 
data by APOE did not reveal any significant association between cases and controls.  The age-, 
and sex adjusted OR for CC genotype vs. TC+TT genotype was 0.92 (95% CI: 0.52, 1.64; 
p=0.78) among APOE*4 carriers and 1.40(95% CI: 0.90, 2.19; p=0.14) among non-APOE*4 
carriers (Table 5.42).   
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5.14. Distribution of the IDE8/T→C (rs551266) Genotype and Allele Frequencies 
in AD Patients and Controls (5.46-5.47) 
 
The genotype (p=0.37) or allele (p=0.13) distribution of T→C transition in IDE gene did not 
reveal any significant association with AD risk (Table 7.46).  The age-, sex and APOE adjusted 
OR for CC genotype vs. TC+TT was 1.38 (95% CI: 0.68-2.80; p=0.37).  We further stratified the 
data by APOE status.  The OR for 1.72 (95% CI: 0.50, 5.97; p=0.39) was among APOE*4 
carriers, and 1.23 (95% CI: 0.50, 3.05; p=0.65) among non-APOE*4 carriers after adjusting for 
age and sex (Table 5.47).  
 
5.15. Distribution of the IDE14/C→T (rs1832196) Genotype and Allele 
Frequencies in AD Patients and Controls (5.51-5.52) 
 
There was no difference in genotype or allele distribution between cases and controls for C→T 
(rs1832196) transition in IDE gene (Table 5.51).  Upon stratification of data by APOE, there 
were no significant difference in genotype and allele distribution among APOE*4 carriers and 
non-APOE*4 carriers.  After adjusting for age and sex effect, the OR for TT genotype vs. 
TC+CC was 2.96 (95% CI: 0.38, 23.27; p=0.30) among APOE*4 carriers and 0.96 (95% CI: 
0.35, 2.60; p=0.94) among non APOE*4 carriers.  The trends for the TT genotype difference 
between APOE*4 carriers and non-APOE*4 carriers were in apposite direction; the TT genotype 
increased the risk for APOE*4 carriers, conversely it has a protective role among non- APOE*4 
carriers. 
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 5.16. Distribution of the HHEX G→A (rs1544210) Genotype and Allele 
Frequencies in AD Patients and Controls (5.56-5.57) 
 
The overall genotype and allele frequencies were similar among cases and controls for the 
HHEX/G→A polymorphisms (rs1832196) (Table 5.56).  The age-, sex-, and APOE adjusted OR 
for AA genotype vs. GA+GG was 0.90 (95% CI: 0.70-1.16; p=0.43).  Stratification of data by 
APOE status revealed that the AA genotype revealed a higher frequency in control subjects 
among APOE*4 carriers (20.92 vs. 24.64), but it was not statistically significant (Table 5.57) 
 
5.17.  Five-site IDE region Haplotype Distribution in AD Cases and Controls 
(Table 5.61) 
 
Haplotype analysis comprising of the IDE, HHEX genes and IGS6 marker was performed. There 
were six haplotypes (H9 ATCCA, H10 ATCCC, H11 ATCTA, H12 ATCTC, H13 ATTCA and 
H20 GCCTC) with a frequency of > 10%.  These most frequent haplotypes accounted for 78 % 
of all haplotypes in the whole samples.  Additional five haplotypes range from 1% to 5 % (H16, 
H19, H25, H26, and H28).  The remaining haplotypes were either not present or occurred at 
frequency with less than 1%. The frequencies for these haplotypes among patients and controls 
and haplotype effects are presented in Table 5.61.  AD patients had a higher frequency of the 
H13/ATTCA (p<0.02), and H27/GTCTA (p=0.007) haplotypes compared to controls.  
Conversely, the H14/ATTCC (p=0.001) and H28/GTCTA (p=0.023) haplotypes were associated 
with a decreased risk of LOAD.  In order to determine the source of effects of the haplotypes 
H13, H14, H27, and H28, we conducted two -site haplotype analyses for the HHEX and IGS 
markers and three-site haplotype analysis for IDE SNPs.  We found no difference among the 
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 distribution of haplotypes between LOAD cases and controls in any of the haplotype groups.  
Comparing AD patients with controls, no significant association was observed concerning the 
other haplotypes.  The overall effect of all haplotypes was not significant. 
 
5.18. Sex- and APOE-Adjusted Age-At-Onset Among IDE, HHEX, IGS6 
Genotypes (Tables 5.38, 5.43, 5.48, 5.53, 5.58) 
 
No association of IDE, HHEX, IGS6 markers with AAO was demonstrated.  Adjusting for the 
effects of gender and APOE did not change the results (Tables 5.38, 5.43, 5.48, 5.53, 5.58).  
Logistic regression analysis to determine possible interaction between the APOE and 
polymorphism in these genes revealed no interaction (Tables 5.40, 5.45, 5.50, 5.55, 5.60). 
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Table 5.62 Distribution of the GSTO1/Ala140Asp Genotype and Allele Frequencies in AD Patients and Controls 
 
  AD Cases  Controls   
Genotype n %  n %   
         
AA  99 10.02 83 12.46  
AC  440 44.53 288 43.24  
CC  449 45.45 295 44.29  
         
Total  988  666   
         
         
Allele frequency        
       p value  
A  0.323  0.341   
C  0.677  0.659 0.231 
                 
Age, sex and APOE adjusted OR      
         
   AA vs. AC+CC  1.34(0.929,1.926;p=0.12) 
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Table 5.63 Distribution of the GSTO1/Ala140Asp Polymorphism Among APOE*4 and non-APOE*4 Carriers 
 
  GSTO1 Genotype Allele Frequency 
APOE*4 n AA AC CC A  C 
AD Cases 581 60 257 264   0.324 0.676 
 % 10.33 44.23 45.44    
        
Controls 137 21 60 56  0.372 0.628 
 % 15.33 43.80 40.88    
        
               
        
non-APOE*4        
AD Cases 402 39 182 181  0.323 0.677 
 % 9.70 45.27 45.02    
        
Controls 529 62 228 239  0.333 0.667 
 % 11.72 43.10 45.18    
        
               
Age and sex adjusted OR      
     AA vs. AC+CC  
  APOE*4   1.31(0.82,2.07;P=0.25) 
  non- APOE*4  1.37(0.84,2.28;P=0.203) 
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Table 5.64 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the GSTO1/Ala140Asp Polymorphism (late 
onset) 
 
 
  Genotype 
 AA AC CC 
Mean AAO 73.37+/-0.69 72.14+/-0.293 72.48+/-0.31 
sample size 94 398 397 
 p value= 0.373 
        
 
 
 
Table 5.65 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the GSTO1/Ala140Asp Polymorphism 
(early and late onset) 
 
 
  Genotype 
 AA AC CC 
Mean AAO 70.00+/-0.95 70.059+/-0.33 70.189+/-0.41 
sample size 108 448 450 
 p value= 0.703 
        
 
 
 
Table 5.66 Summary of AAO Analysis GSTO1/Ala140Asp Polymorphism  
 
  
AAO 
(late  onset) 
AAO 
(early and late) 
Effect ANOVA p value ANOVA p value 
N 917 1037 
GSTO1 Genotype 0.462 0.790 
APOE < 0.0001 < 0.011 
Sex 0.111 0.111 
GSTO1 Genotype * APOE 0.386 0.505 
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Table 5.67 Distribution of the GSTO2/-183A→G Genotype and Allele Frequencies in AD Patients and Controls 
 
  AD Cases  Controls   
Genotype n %   n %    
         
AA  485 49.04  355 48.50   
AG  419 42.37  308 42.08   
GG  85 8.59  69 9.43   
         
Total  989   732    
         
         
Allele frequency        
       p value  
A  0.702   0.695    
C  0.298   0.305  0.93  
                 
Age, sex and APOE adjusted OR      
         
   GG vs. AG+AA  0.92(0.66-1.29;p=0.63) 
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Table 5.68 Distribution of the GSTO2/-183A→G Polymorphism Among APOE*4 and non-APOE*4 Carriers 
 
        
   Genotype Frequency Allele Frequency 
APOE*4 n AA AG GG  A  C 
AD Cases 580 276 249 55  0.691 0.309 
 % 47.59 42.93 9.48    
        
Controls 148 68 60 20  0.662 0.338 
 % 45.95 40.54 13.51    
       p=0.34 
               
        
non-
APOE*4        
AD Cases 404 205 169 30  0.717 0.283 
 % 50.74 41.83 7.43    
        
Controls 583 287 247 49  0.704 0.296 
 % 49.23 42.37 8.40    
       p=0.34 
                
Age and sex adjusted OR      
     GG vs. AG+AA  
  APOE*4   0.72(0.42,1.26;p=0.25) 
  non- APOE*4  0.80(0.49-1.31;p=0.38) 
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Table 5.69 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the GSTO2/-183A→G Polymorphism (late 
onset) 
 
  Genotype 
 AA AG GG 
Mean AAO 72.46±0.29 72.30±0.30 73.25±0.73 
sample size 432 378 78 
 p-value= 0.42 
        
 
 
 
Table 5.70 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the GSTO2/-183A→G Polymorphism (early 
and late onset) 
 
  Genotype 
 AA AG GG 
Mean AAO 70.34±0.37 70.05±0.43 70.25±1.05 
sample size 488 429 88 
 p-value= 0.28 
        
 
 
 
Table 5.71 Summary of AAO Analysis  Among the GSTO2/-183A→G Polymorphism 
  
AAO 
(late onset) 
AAO 
(early and late) 
Effect ANOVA p value ANOVA p value 
N 918 1038 
GSTO2 Genotype 0.61 0.31 
APOE < 0.0001 < 0.0001 
Sex 0.127 0.02 
GSTO2 Genotype * APOE 0.25 0.92 
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Table 5.72 Distribution of PRSS11/IVS8-36T→C Genotype and Allele Frequencies in AD Patients and Controls 
 
  AD Cases  Controls   
Genotype n %  n %    
         
TT  34 3.43  32 4.78   
CT  317 32.02  205 30.64   
CC  639 64.55  432 64.57   
         
Total  990   669    
         
         
Allele frequency        
         
T  0.194   0.201    
C  0.806   0.799  p=0.62  
                 
Age, sex and APOE adjusted OR      
         
   TT vs. CT+CC  1.249 (0.719,2.168;p=0.43) 
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Table 5.73 Distribution of the PRSS11/IVS8-36T→C Polymorphism Among APOE*4 and non-APOE*4 Carriers 
 
        
   Genotype Frequency Allele Frequency 
APOE*4 n TT CT CC  T  C 
AD Cases 581 18 182 381  0.188 0.812 
 % 3.10 31.33 65.58    
        
Controls 148 5 46 97  0.189 0.811 
 % 3.38 31.08 65.54    
       p=0.97 
               
        
non-
APOE*4        
AD Cases 404 16 133 255  0.204 0.796 
 % 3.96 32.92 63.12    
        
Controls 586 30 182 374  0.206 0.794 
 % 5.12 31.06 63.82    
       p=0.91 
               
Age and sex adjusted OR      
     TT vs. CT+CC  
  APOE*4   1.20 (0.43,3.35;P=0.725) 
  non- APOE*4  1.25 (0.644,2.415;P=0.513) 
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Table 5.74 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the PRSS11/IVS8-T→C Polymorphism 
(late onset) 
 
  Genotype 
 TT TC CC 
Mean AAO 71.582±1.16 72.718±0.365 72.351±0.251 
sample size 29 283 577 
 p value= 0.995 
        
 
 
 
 
Table 5.75 Sex and APOE adjusted Age-at-Onset (Mean ± SE) Among the PRSS11/IVS8-T→C Polymorphism 
(early and late onset) 
 
  Genotype 
 TT TC CC 
Mean AAO 70.705±1.662 70.291±0.483 70.072±0.339 
sample size 30 327 648 
 p value= 0.488 
        
 
 
 
 
Table 5.76 Summary of AAO Analysis Among the PRSS11/IVS8-T→C 
  
AAO 
(late onset) 
Age at Onset 
(early and late) 
Effect ANOVA p value ANOVA p value 
N 919 1037 
PRSS11 Genotype 0.981 0.497 
APOE < 0.0001 < 0.0001 
Sex 0.109 0.008 
PRSS11 Genotype * APOE 0.191 0.051 
  0.993  
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 Table 5.77 Estimated 3-site GSTO1, GSTO2, PRSS11 Haplotype Distribution in AD Cases and Controls 
EH Methods 
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5.19. Distribution of the GSTO1/Ala140Asp Polymorphism (5.62-5.64)  
 
There was no significant difference in genotype or allele distribution between cases and controls 
for GSTO1/A→C  (Asp→Ala) polymorphism at exon 4 (Table 5.62)  The age, sex, and APOE 
adjusted OR for developing AD between AA and AC+CC genotypes was 1.34 (95% CI: 0.93-
1.93; p=0.119).  Stratification of data by APOE*4 status showed no significant difference in 
either genotype or allele frequencies among APOE*4 carriers or non- APOE*4 carriers (Table 
5.64). AAO was analyzed as a quantitative trait among GSTO1 genotypes in AD cases.  
However, no significant association was observed, even after adjusting for the effects of gender 
and APOE. (p=0.37) (Table 5.65). 
 
5.20. Distribution of the GSTO2/-183→G Polymorphism (Tables 5.67-5.68) 
 
The genotype (p=0.37) or allele (p=0.13) distribution of A→G polymorphism in the GSTO2 
gene did not reveal any significant association with AD risk (Table 5.67).  The age-, sex and 
APOE adjusted OR for GG genotype vs. AG+AA was 0.92 (95% CI: 0.66-1.29; p=0.63).  We 
further stratified the data by APOE status.  The OR was 0.72(95% CI: 0.42, 1.26; p=0.25) among 
APOE*4 carriers, and 0.80(95% CI: 0.49-1.31; p=0.38) among non-APOE*4 carriers after 
adjusting for age and sex (Table 7.68). The GSTO2 A→G polymorphism was not associated 
with AAO either (Table 5.69).   
 
 
78 
 5.21.  Distribution of the PRSS11/IVS8-36T→C Polymorphism (Tables 5.72-5.73) 
 
The overall distribution of the PRSS11/T→C polymorphism was similar between cases and 
controls (p=0.43) (Table 5.72).  The OR for T carriers (CT+TT vs. CC) was 1.25 (95%CI: 0.72-
2.17; p=0.43).  After adjusting for effect of age, sex and APOE, there was no significant effect of 
the PRSS11 polymorphism on AD risk (Table 5.73).  Association analysis between PRSS11 and 
AAO did not find any significant association among cases AD (p=0.99) (Table 5.64).  
 
5.22. Estimated 3-site GSTO1, GSTO2, PRSS11 Haplotype Distribution (Tables 
5.77) 
 
Estimated haplotype frequencies for the three markers are presented in Table 5.77. Three 
(haplotypes 3, 5, 6) of the 8 possible haplotypes accounted for 90% of the total chromosomes 
examined.  Haplotype 8 was absent in the subjects examined. A marginal statistically significant 
difference was observed for the frequency of haplotype 1 between LOAD cases and controls 
(0.023 vs. 0.035; p=0.04). In order to determine the source of the haplotype 1 effect, we 
conducted two-site haplotype analyses and found the effect to be coming from the GSTO1 and 
GSTO2 polymorphisms (p=0.06). The overall haplotype frequencies were not statistically 
different between LOAD cases and controls (p=0.50). 
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6. Discussion 
 
 
Alzheimer’s disease (AD), a progressive, neurodegenerative disease, is a significant public 
health problem in the United States.  It is the most common form of dementia among the elderly.  
Although, it has been described since 1907 (Alzheimer 1907), no cure or universally accepted 
effective treatment has been established.  Studying factors that play a role in risk and 
pathogenesis of LOAD may lead to development of new therapies and give an insight to the 
etiology of LOAD.  Both genetic and environmental factors have been implicated in the etiology 
of AD.  Heredity has been shown to be major causal factor in LOAD (Bergem et al. 1997).  In 
twin studies the role of genetic factors has been estimated to be as much as 74% (Bergem et al. 
1997; Daw et al. 2000).  Despite the evidence for substantial genetic effect in the etiology of 
LOAD, to date APOE which accounts for 20-30 % of AD risk (Slooter et al. 1998, Seshadri et 
al.1995) is the only established risk factor in the development of LOAD.  A large number of 
candidate genes have been evaluated for development of LOAD.  However, except for APOE 
none of them are consistently proven to be associated with LOAD.  Complex heterogeneous 
nature of LOAD makes it difficult to find new risk factors in the development of AD.  Gene-gene 
interaction, gene-environment interaction can explain some of the replication failures. It might 
make it difficult to detect mild to moderate effects.  Evidence for the existence of additional 
candidate genes for AAO of LOAD is provided by Daw and colleagues (2000), who estimated 
the presence of four to seven additional loci with at least one locus making a contribution several 
times greater than that of APOE.   In addition to this, linkage studies have identified several 
promising chromosomal regions to harbor additional AD genes, including chromosome 10 
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 (reviewed in Kamboh 2004).  A broad linkage peak encompassing >60 cM region between 
chromosome 10q21 and 10q25 has been implicated that influence both AD risk and AAO 
(Bertram et al. 2000; Ertekin-Taner et al. 2000; Myers et al., 2000; Li et al. 2003).  There are 
more than 300 genes in this broad genomic region of chromosome 10 and thus the task of 
identifying the chromosome 10 candidate gene locus is daunting.  One approach is to focus on 
the known candidate genes in the region.  There are number of promising candidate genes in this 
region that are involved in either in the production, processing or clearance of Aβ peptide and 
include PLAU, IDE, HHEX, GSTO1, GSTO2, and PRSS11.  Previously, some groups have 
examined the role of these genes with AD risk or AAO, but the results have been equivocal.  
However, most of the published studies used relatively small number of cases and controls and 
thus fall short of providing conclusive results.  The objective of this study was to use a well 
powered case-control cohort to examine the role of selected positional and biological candidate 
genes on chromosome 10.  Below, we provide the summary of our findings in relation to the 
published data. 
 
 
 
6.1. Choline Acetyltransferase (CHAT) 
 
A number of factors render CHAT a reasonable candidate gene for AD.  CHAT is both a 
positional and functional candidate gene for AD.  CHAT is mapped near the linked region on 
chromosome 10q11 at 50.2 cM. One of the characteristic features of AD is the degeneration and 
dysfunction of the cholinergic system (Bowen et al. 1976; Davies and Maloney 1976; Perry et al. 
1977; Whitehouse et al. 1982) that is believed to contribute significantly to the cognitive 
symptoms associated with the disease. CHAT and the vesicular acetylcholine transporter 
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 (VACHT) proteins are specifically required for cholinergic neurotransmission: CHAT catalyses 
the biosynthesis of the neurotransmitter acetylcholine (ACh) and VACHT it is responsible for 
the translocation of cytoplasmic ACh into synaptic vesicles.  CHAT appears to play an important 
role in the neurodegeneration process, as its activity has been shown to be reduced by 50%–90% 
in AD patients compared with age-matched controls (Perry et al. 1978; Davies 1979) and it is 
correlated with the severity of dementia (Wilcock et al. 1982; Bierer et al. 1995). The relatively 
few effective drug treatments that slow the progressive cognitive deterioration in AD have 
generally targeted enhancement of the cholinergic system via cholinesterase inhibitors, such as 
donepezil and galanthamine, which indirectly increase the synaptic concentration of ACh 
(Nordberg and Svensson 1998) Thus, both CHAT and VACHT are obvious functional 
candidates for involvement in AD.   Since the VACHT gene is located within the first intron of 
the CHAT gene (Berse et al. 1999) examining genetic variation in one gene may also reflect the 
variation in the other gene.  For this reason, we restricted our focus only on the CHAT gene. 
We have investigated the association of 3 polymorphisms in the CHAT gene on 
chromosome 10 with the risk of AD.  Two of these polymorphisms are located in the coding 
region: exon 5/A120T (rs3810950) and exon S/D7N (rs1880676); the third one is 140 bp 
downstream of exon 9, 11604 G→A (rs868750).   We found suggestive association with the 
exon 5 and intron 9 SNPs. 
Our initial analysis of the CHAT/A120T polymorphism showed no association with AD.  
However, when the sample was stratified by APOE status, the A allele of CHAT/A120T was 
associated with protective effect among non APOE*4 carriers.   Since we observed a modest 
association after multiple comparisons, these results should be interpreted with caution.  Previous 
studies have produced variable results for the association of the CHAT/A120 T polymorphism 
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 with AD.  Originally, Mubumbila et al. (2002) reported a significant association of the 
CHAT/A120T polymorphism in 122 LOAD cases and 112 controls in a French-German 
population (OR=3.7; p=0.0005).  However, it was not confirmed by subsequent studies (Schwarz 
et al. 2003, Harold et al. 2003), including ours. While the frequency of the A allele among 
controls in all studies was 24-28%, Mubumbila et al. (2002) observed a relatively high frequency 
of this allele in AD cases (48%), which was not the case in other studies (23-28%).   Of the three 
published studies, only Schwarz et al. (2003) examined the distribution of the CHAT/A120T 
polymorphism by APOE genotype, but they did not observe any significant association.  
However, these sample sizes were too small for meaningful interpretation of the data. 
The only comprehensive study that examined multiple SNPs in the CHAT gene comes 
from Harold’s group (Harold et al. 2003).  In their study, they identified 17 SNPs, including the 
three SNPs examined in our study.  Their study comprised 3 independent samples, namely UK1, 
UK2 Caucasian groups, and UK3, a Northern Irish Caucasian group.  Initially, they analyzed all 
SNPs in the UK1 sample and found suggestive association with the intron 9 (p=0.03) and exon S 
(p=0.09) SNPs.  However, they could not replicate these findings in the UK2 and UK3 samples. 
This is possibly due to the fact that the sample sizes in each of the three groups were small (AD 
cases range 119-209; controls range 136-222).  We examined these two SNPs in our larger case-
control cohort to further asses their contribution with the risk of AD.  Our study reveals both 
allelic (p=0.03) and genotypic (p=0.007) association of the intron 9 polymorphism with AD.  
The AA genotype was associated with significant AD risk (OR: 2.37; p=0.007).  Stratification of 
data by APOE genotype revealed that association was confined among non-APOE*4 carriers 
only (OR: 2.94; p=0.007).  Thus, our data support the initial finding in the UK1 sample that the 
A allele of the intron 9 polymorphism may confer significant risk in the development AD.  
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 However, the effect seems small as this was not observed in the UK2 and UK3 samples.  To date 
our study is the largest study that examined the association of AD with CHAT polymorphisms.   
The biological implication of intron 9 association with AD is not clear.  For many 
variants such as premature stop codons, missense mutations, mutations in consensus nucleotides 
of splice sites, it can easily be inferred that they are likely to contribute to a phenotype.  This 
polymorphism may be in linkage disequilibrium with a functional polymorphism in this gene.  
However, we can not exclude the possibility of linkage with another marker elsewhere in the 
10q11 region that is involved in the development of AD.  It is also possible that the intron 9 
region of the CHAT gene that encompasses the polymorphic site harbor regulatory elements and 
thus this polymorphic site might be functional by itself. 
We also evaluated the distributions 3-site haplotypes in cases and controls.  However, 
haplotype frequencies of the CHAT exon S and intron 9 gene polymorphisms were similar in 
patient and control subjects.   
In addition to the association with AD risk, we also examined the association between 
these SNPs and AAO.  We found no correlation between the three CHAT polymorphisms 
examined and AAO.  These result are in accordance with the findings of Schwarz et al. (2003); 
the only other study in addition to ours that also examined the association of the exon 5 
polymorphism with AAO. 
In summary, we have investigated the impact of the three CHAT polymorphisms with 
AD risk and AAO.  We detected both allelic and genotypic association of the intron 9 
polymorphism with AD risk.  The rare AA genotype appears to confer a modest risk for the 
development of AD in a recessive fashion.  In addition, we observed APOE-dependent effect of 
the exon 5 polymorphism with AD risk.  Although these associations are marginal, they suggest 
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 the presence of putative functional variant in the CHAT gene or nearby genes.  Moreover our 
results suggest that the exon 5 polymorphism has a potential role in earlier development of 
LOAD. 
6.2. Plasminogen Activitory, Urinary(PLAU) 
 
PLAU converts plasminogen to plasmin.  Plasmin is involved in the processing of amyloid 
precursor protein, one of the hallmarks of AD.  (Finckh et al. 2003)  PLAU is located on 
chromosome 10q22.2 between two regions showing linkage to LOAD (Bertram et al., 2000); 
Ertekin-Taner et al. (2000); Myers et al. (2000).  PLAU seems to play a significant role in the 
prevention of neurodegeneration process, as reduced levels of plasmin has been shown in the 
brain tissues of AD patients. This suggests that plasmin downregulation may cause amyloid 
plaque deposition in sporadic AD (Ledesma et al., 2000).  Moreover, increased levels of Aβ have 
been observed in PLAU knockout mice (Tucker et al. 2000).    Tucker et al. (2000) demonstrated 
that plasmin pathway is induced by aggregated Aβ, which can lead to degradation of Aβ and 
inhibition of its action. The same group suggested that urokinase-type plasminogen activator 
(uPA), PLAU’s protein product, in combination with plasminogen, prevents Aβ toxicity, 
deposition and fibril formation.  These evidences suggest that PLAU could play an important 
role in the pathogenesis of AD.  
Previously two studies have examined the role of PLAU genetic variation with AD risk.  
Finckh et al. (2003) screened 347 cases and 291 controls for the PLAU/Pro141Leu 
polymorphism and found significant association (OR= 1.89; p= 0.0004).   More recently, Myers 
et al. (2004) examined the role of 8 polymorphisms spanning the entire PLAU gene with AD 
risk, including Pro141/Leu.  With the exception of the 3’ UTR polymorphism that yielded a 
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 suggestive association (p=0.15), Myers et al. (2004) did not find significant association with the 
remaining markers.  Although, the study performed by Myers et al. (2004) covered the entire 
variation coding region and surrounding intron-exon junctions, and one SNP in the 5’ UTR, it 
did not cover SNPs in the intronic and promoter region. 
As a part of Seattle SNP discovery panel, the entire PLAU gene has been screened in 24 
blacks and 23 Caucasians (http://pga.gs.washington.edu/data/plau /).  Among Caucasian 37, 
SNPs have been identified, but only 15 exist at a frequency of 5% or above.  Based on their 
strong LD pattern (r2=0.80), the 15 SNPs are placed into 3 bins and only one tagSNP from each 
bin is required for genotyping purposes. (Carson et al. 2004). 
We chose these 3 tagSNP in this study that are located in intron 5, intron 9, and 3’ UTR.  
The intron 9 and 3’ UTR SNPs were also used by Myers et al. (2004) in their association study.  
In our study, only the 3’ UTR polymorphism revealed a significant association (OR=0.71; 
p=0.02), which was confined to APOE*4 carriers (OR=0.58; p=0.02).  Individuals with the CC 
genotype appear to be protective against the risk of AD.  The frequency of the CC genotype was 
19 % in total controls and 15 % in total cases.  However, among APOE*4 carriers, its frequency 
was 23% in controls and only 15 % in cases.  As noted above, among the 8 SNPs examined by 
Myers et al., (2004) only the 3’ UTR revealed a suggestive association (p=0.15).  The lack of 
significant results in Myers et al. (2004) study could be due to power issue, because their sample 
size was smaller (291 cases and 290 controls) than ours (989 cases and 690 controls).  It is 
possible that the 3’ UTR SNP by itself is functional, as these functionally independent 
instability-regulating sites have been found in the 3’ region of uPA mRNA (Nanbu et al. 1996).  
The other explanation is that the 3’UTR SNP may be in LD with a functional SNP in the 3’ UTR 
of PLAU, as by itself it has only modest effect on AD risk.  Although we used the tagSNPs in 
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 this study, if a functional SNP is not associated with a tagSNP it can easily go undetected.  Since 
the putative functional SNP is not tightly linked with the tagSNP, it may explain the modest 
association observed with the 3’ UTR tagSNP.  In view of suggestive association seen in  two 
studies with the PLAU/3’UTR SNP, it β be important in the future studies to screen all common 
and less common variants in the PLAU gene in association studies.  The use of common 
tagSNPs (>5% minor allele frequency) in association studies assumes the common disease-
common variant hypotheses (Lohmneller et al. 2003).  However, recent data indicate that 
multiple rare variants in a gene can also explain the association with common diseases (Cohen et 
al. 2004). 
In addition to risk, we also evaluated the role of 3 PLAU tagSNPs with AAO of AD.  
Suggestive association were observed with the 3’ UTR (p=0.10) and intron 9 (p=0.04) 
polymorphisms.  Interestingly the CC genotype of the 3’ UTR polymorphism that was associated 
with AD risk had the lowest mean of AAO than the other 2 genotypes (70.97±0.48 vs. 
72.33±0.31, 72.14±0.34). To our knowledge, it is the first study that examined the role of PLAU 
SNPs with AAO.  
In summary, we have examined 3 tagSNPs in the PLAU gene and our data suggest a 
modest association of tagSNP with both AD risk and AAO. 
 
 
6.3. Insulin-Degrading Enzyme (IDE) 
 
 
In the brain, IDE has been reported to be expressed predominantly in neurons (Bernstein et al. 
1999; Vekrellis et al. 2000; Cook et al. 2003).  A hallmark of AD is the formation of Aβ deposits 
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 in the brain of AD patients.  That contributes to brain cell dysfunction, loss of neuron mass, and 
ultimately brain cell death. Studies demonstrate that Aβ is degraded by IDE (Kurochkin and 
Goto 1994; Qiu et al. 1998).  IDE appears to play an important role in the neurodegeneration as 
increased Aβ levels has been shown in the brain of IDE deficient mice (Farris et al. 2003).  In an 
in vitro study, it has been shown that recombinant rat insulin hydrolyzes Aβ peptides to products 
that are non neurotoxic and these new products did not deposit in amyloid plaques, suggesting a 
possible role of insulin in the treatment of AD (Mukherjee et al. 2001).  The level of IDE is 
reduced 50 % in the brain of APOE*4-positive patients, compared to that of controls and 
APOE*4-negative patients (Cook et al. 2003).  This indicates that reduced IDE expression is 
associated with a significant risk factor for AD and IDE affects Aβ metabolism by interacting 
with APOE.  Furthermore, Hyperinsulinemia was shown to be associated with a significant 
decline in memory (Luchsinger et al. 2004)
A number of studies have examined the role of IDE genetic variants with AD risk, but 
results are not consistent.  The first study that examined the IDE gene looked at the common 
genetic variation (>5%) in this gene covering all the coding and 5’ region  in relation to AD risk 
and found no significant association (Abraham et al. 2001).  Later, same data further stratified by 
APOE status that yielded a possible association among non-APOE*4 carriers (Edland et al. 
2003).  Studies of IDE variants in different ethnic groups yielded variable results. While IDE 
was associated with AD risk in an APOE*4 dependent fashion in Han Chinese (Bian et al. 2004), 
no association has been found in a Japanese population in selected SNPs studied (Sakai et al 
2004).  Boussaha et al. (2002) with the largest cases (n=240) among all the aforementioned 
groups genotyped two intronic SNPs in French population and found no significant association.  
An additional study examined a large 276-kb region that harbors IDE gene as well in relation to 
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 AD risk and quantitative traits associated with AD risk (Prince et al. 2003).  While no association 
was observed with AD risk, several significant associations were found with the severity of 
disease as measured by quantitative traits, including Mini-Mental State Examination (MMSE) 
scores, microtubule-associated protein tau levels in cerebral spinal fluid, the AAO, and the 
degree of brain pathology. It should be emphasized, however, that as opposed to the AAO, which 
is static over time and provides meaningful genetic association data, the initial association of 
genotype and severity of disease may be difficult to interpret unless it is confirmed in 
independent studies. Recently, Ertekin-Taner et al. (2004) analyzed the same IDE markers 
previously shown to be associated with quantitative traits (Prince et al. 2003) and two additional 
markers, and found significant associations with Aβ42 levels and LOAD. However, the role of 
Aβ42 as a surrogate AD marker has some limitations; elevated levels of Aβ42 have been 
reported in only approximately 10 % of sporadic AD patients (Tomaoka et al. 1996).  This 
suggest that markers associated with Aβ42 levels might represent subset AD group associated 
with elevated Aβ serum levels  thus, additional studies in independent samples could be 
important in clarifying the role of IDE genetic variation in relation to quantitative traits 
associated with AD.   
In our study we examined 5 SNPs extending locally around IDE in a large Caucasian 
case-control cohort.  Three of these SNPs; IDE7, IDE14, and HHEX23 were haplotype tagging 
markers that captured the common polymorphisms (>5%) in the 276.5-kb genomic region 
harboring the IDE, kynesin like 1 (KNSLI), and HHEX genes (Prince et al. 2003).  In addition, 
we examined two SNPs IGS6 and IDE8.  IGS6 is outside of this haplotype block, and in a 
preliminary analysis (Prince et al. 2003), it has been shown to be associated with AD risk among 
non-APOE*4 carriers.  IDE8 has been shown to be associated with AD risk in two independent 
89 
 studies (Prince et al. 2003; Edland et al. 2003).  To increase the likelihood of finding an 
association in this region of the chromosome 10, we tested the same SNPs that were shown by 
others groups to be associated with AD and quantitative traits (Ertekin-Taner et al. 2004; Prince 
et al. 2003).  In our study, neither variant was associated with LOAD or AAO when replication 
was sought in 1012 LOAD cases and 771 controls.  Likewise, there was no difference among the 
cases and controls after stratifying the data by APOE status.  Haplotype analysis of all typed 
SNPs indicated a protective effect associated with two of the haplotypes: H14/ATTCC 
(p=0.0001), and H28/GTCTC (p=0.024) and risk with two additional haplotypes: H13/ATTCA 
(p=0.02) and H27/GTCTA (p=0.007).  However, these were rare haplotypes and the overall 
effect of all haplotypes was not significant.  We conclude that analysis of our study provides no 
compelling evidence that common variation in the IDE gene contributes to AD susceptibility or 
AAO in Caucasians. 
Several factors may explain the lack of association in our sample and some of previously 
reported positive but modest associations.  First, most of the previous studies used relatively 
small sample sizes that are not sufficient to make a meaningful interpretation.  Second, 
discrepancies can arise due to differences in the population studied  Third, different study design 
between populations can lead to different outcomes:  such as family-based population (Ertekin-
Taner et al. 2004) or sporadic AD population (Abraham 2001; Edland 2003; Boussaha et al. 
2002; Bian et al. 2004; Sakai et al. 2004).  Fourth, different outcomes were studied; including 
AD risk, AAO or intermediate quantitative traits, MMSE scores, microtubule-associated protein 
tau levels in cerebral spinal fluid, and the degree of brain pathology.  Fifth, different markers 
were studied in different investigations.  We have investigated the same SNPs studied by 
Ertekin-Taner et al. (2004) and Prince et al. (2003), but we were unable to replicate the 
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 association of IDE common variants with risk and AAO of AD despite using large case-control 
samples.  
In conclusion, the results of this study do not support an association of the IDE gene with 
AD susceptibility or AAO.  However, in our study we did not evaluate intermediate quantitative 
trait for AD such as Aβ levels and it is possible that the effect of IDE on AD comes through 
modulating this traits. 
 
 
6.4. Glutathione S-transferase omega 1 and 2 (GSTO1 and GSTO2)  protease 
serine 11 (PRSS11) 
 
Using differential gene expression approach in brains from AD patients and controls, Li et al. 
(2003) found that four of the 52 differentially expressed genes (stearoyl-COA desaturase; NADH 
ubiquinone oxidoreductase 1β complex 8, PRSS11 and GSTO1) were located under the linkage 
peak for AAO on chromosome 10.  Thus they targeted these genes for association analysis using 
a large family-based sample.  Two of the four differentially expressed genes, PRSS11 and 
GSTO1, and a linked member of the GST omega class, GSTO2, showed significant association 
with AAO in AD.  In order to confirm this association, we evaluated the role of reported GSTO1, 
GSTO2 and PRSS11 polymorphisms with AAO in 990 LOAD patients.  We also assessed if 
these polymorphisms were associated with AD risk in a large case-control cohort.  Despite using 
large AD cases, we were unable to confirm the association of these polymorphisms with AAO. 
Li et al. (2003) obtained maximum p-values of 0.007 for GSTO1, 0.005 for GSTO2 and 0.028 
for PRSS11 for their association with AAO of AD.  Similar p-values for GSTO1 and GSTO2 
were interpreted to be due to strong LD between the two makers.  However, GSTO1/GSTO2 
markers were not in LD with the PRSS11 marker.  Based on the LD patterns and strength of 
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 association results, Li et al. (2003) concluded that GSTO1/GSTO2 rather than the PRSS11 
region may harbor the susceptibility alleles for AAO despite the fact the later showed the most 
significant difference in the gene expression profiling experiment.  In addition to the association 
with AAO in AD, Li et al. (2003) also found significant association of GSTO1/GSTO2 
polymorphisms with AAO in Parkinson disease (p=0.026, 0.042, respectively), but not with 
PRSS11 (p=0.06).   
Although GSTO1/GSTO2 are compelling biological (Laliberte et al. 2003) and positional 
candidate genes and the expression and association data of Li et al. (2003) provide further 
credence to their possible involvement in the etiology of AD, we were unable to confirm their 
genetic association in our sample.  Our failure to confirm the reported association with AAO is 
unlikely to be attributed to low power because our sample had >80% power to detect a mean 
AAO difference of 1.1 years between genotypes.  Although Li et al. (2003) did not indicate mean 
AAO difference between GSTO genotypes, this difference was highly significant (p = 0.007 - 
0.005) and should have been easily detected in our large sample.  In our AD sample the mean 
AAO ± SD was 70.58 ± 8.82 years (range 33-91), while in the published family AD sample the 
mean AAO was 72 ± 8 years (range 40-97).  Although Li et al. (2003) did not specify the 
number of early-onset cases (<60 years), from their mean AAO of 72 years, it appears that the 
bulk of their sample comprised LOAD cases, similar to what we used in this investigation.  The 
different outcomes in two studies may be due to difference in study design, as we used sporadic 
AD cases whereas Li et al. (2003) used familial cases.  It is possible that the effect of these genes 
is stronger in familial AD due to shared common genetic background than in sporadic AD, thus 
making it difficult to readily detect it in sporadic AD cases.  To address this issue, we performed 
a post-hoc analysis on 126 EOAD cases (range 33 – 59 years), as 34% of EOAD cases had a 
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 family history of dementia.  However, there was no significant association with AAO in this 
small sample.  Additional studies on familial and sporadic AD samples are needed to clarify the 
published association of GSTO1/GSTO2 with AAO.  On the other hand, our data suggest that 
the GSTO1 and GSTO2 genes might modestly affect the risk of AD as revealed by haplotype 
analyses.  Similar to our findings, recently Lee et al. (Lee et al.2004) reported no association of 
GSTO1 polymorphism with AAO in Caribbean Hispanics but found a modest association with 
AD risk.   
In this study we tested the hypothesis that the reported association of GSTO1 and GSTO2 
SNPs is real and thus we did not examine additional polymorphisms in these genes.  Since 
GSTO1 and GSTO2 are potential candidate genes for AD, additional SNPs in these genes need 
to be analyzed to further explore their roles in the etiology of AD. 
 
6.5. Summary 
 
Several independent linkage studies have implicated a broad interval of > 50 Mb on chromosome 
10.  It is not clear whether this linkage findings indicate the existence of multiple genes or 
represent chance variation of the location because estimates of location of genes based on 
linkage studies can vary 30 cM or more for complex disorder (Roberts et al. 1999).   Similar 
discrepancies in linkage results were found on chromosome 19 that eventually resulted in 
identification of APOE gene.  Thus, it seems likely that at least one AD risk gene exist on 
chromosome 10.  In this study, association studies for 14 markers on chromosome 10 were 
performed in a large case-control cohort comprising 1012 white LOAD subjects and 771 white 
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 control subjects.  No significant associations were observed with any of the polymorphisms 
examined in the HHEX, GSTO1, GSTO2, and PRSS11 genes.  
Of the 3 CHAT SNPs examined, we detected both allelic and genotypic association of the 
intron 9 polymorphism with AD risk.  The rare AA genotype appears to confer a modest risk for 
the development of AD in a recessive fashion (OR: 2.37; p=0.007).  In addition, we observed 
APOE-dependent effect of the CHAT exon 5 polymorphism with AD risk (OR=0.76; p=0.046).  
Although these associations are modest, they suggest the presence of putative functional variants 
in the CHAT gene or nearby genes. 
In the PLAU gene we have examined 3 tagSNPs and found a modest protective effect 
with one SNP in the 3’ UTR (OR=0.71; p=0.02), which was confined to APOE*4 carriers 
(OR=0.58; p=0.02).  In our analysis of the association of the candidate genes with AAO, 
suggestive association were observed only with the PLAU 3’ UTR (p=0.10) and intron 9 
(p=0.04) polymorphisms. 
In conclusion, our data on large number of AD cases and control suggest that genetic 
variation in two positional candidate genes (PLAU and CHAT) may affect the risk and AAO of 
LOAD and variation. 
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